WO2010114929A1 - Overnight closed-loop insulin delivery with model predictive control and glucose measurement error model - Google Patents
Overnight closed-loop insulin delivery with model predictive control and glucose measurement error model Download PDFInfo
- Publication number
- WO2010114929A1 WO2010114929A1 PCT/US2010/029492 US2010029492W WO2010114929A1 WO 2010114929 A1 WO2010114929 A1 WO 2010114929A1 US 2010029492 W US2010029492 W US 2010029492W WO 2010114929 A1 WO2010114929 A1 WO 2010114929A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- glucose
- insulin
- sensor
- delivery
- model
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
- A61M5/14—Infusion devices, e.g. infusing by gravity; Blood infusion; Accessories therefor
- A61M5/168—Means for controlling media flow to the body or for metering media to the body, e.g. drip meters, counters ; Monitoring media flow to the body
- A61M5/172—Means for controlling media flow to the body or for metering media to the body, e.g. drip meters, counters ; Monitoring media flow to the body electrical or electronic
- A61M5/1723—Means for controlling media flow to the body or for metering media to the body, e.g. drip meters, counters ; Monitoring media flow to the body electrical or electronic using feedback of body parameters, e.g. blood-sugar, pressure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/145—Measuring characteristics of blood in vivo, e.g. gas concentration, pH value; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid, cerebral tissue
- A61B5/14532—Measuring characteristics of blood in vivo, e.g. gas concentration, pH value; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid, cerebral tissue for measuring glucose, e.g. by tissue impedance measurement
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/145—Measuring characteristics of blood in vivo, e.g. gas concentration, pH value; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid, cerebral tissue
- A61B5/1495—Calibrating or testing of in-vivo probes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
- A61M5/14—Infusion devices, e.g. infusing by gravity; Blood infusion; Accessories therefor
- A61M5/142—Pressure infusion, e.g. using pumps
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
- G16H20/00—ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance
- G16H20/10—ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance relating to drugs or medications, e.g. for ensuring correct administration to patients
- G16H20/17—ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance relating to drugs or medications, e.g. for ensuring correct administration to patients delivered via infusion or injection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
- A61M5/14—Infusion devices, e.g. infusing by gravity; Blood infusion; Accessories therefor
- A61M5/142—Pressure infusion, e.g. using pumps
- A61M2005/14208—Pressure infusion, e.g. using pumps with a programmable infusion control system, characterised by the infusion program
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
- A61M5/14—Infusion devices, e.g. infusing by gravity; Blood infusion; Accessories therefor
- A61M5/142—Pressure infusion, e.g. using pumps
- A61M2005/14288—Infusion or injection simulation
- A61M2005/14292—Computer-based infusion planning or simulation of spatio-temporal infusate distribution
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
- A61M5/14—Infusion devices, e.g. infusing by gravity; Blood infusion; Accessories therefor
- A61M5/142—Pressure infusion, e.g. using pumps
- A61M2005/14288—Infusion or injection simulation
- A61M2005/14296—Pharmacokinetic models
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M2205/00—General characteristics of the apparatus
- A61M2205/50—General characteristics of the apparatus with microprocessors or computers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M2205/00—General characteristics of the apparatus
- A61M2205/50—General characteristics of the apparatus with microprocessors or computers
- A61M2205/52—General characteristics of the apparatus with microprocessors or computers with memories providing a history of measured variating parameters of apparatus or patient
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M2205/00—General characteristics of the apparatus
- A61M2205/70—General characteristics of the apparatus with testing or calibration facilities
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M2230/00—Measuring parameters of the user
- A61M2230/20—Blood composition characteristics
- A61M2230/201—Glucose concentration
Definitions
- the invention is generally directed to an integrated system of blood glucose level detection and use of that information in setting insulin delivery parameters, and more particularly, to the use of actual sensor data in characterizing a sensor for use in performing pre-clinical closed-loop trial studies in silico.
- Diabetes is a metabolic disorder that afflicts tens of millions of people throughout the world. Diabetes results from the inability of the body to properly utilize and metabolize carbohydrates, particularly glucose. Normally, the finely-tuned balance between glucose in the blood and glucose in bodily tissue cells is maintained by insulin, a hormone produced by the pancreas which controls, among other things, the transfer of glucose from blood into body tissue cells. Upsetting this balance causes many complications and pathologies including heart disease, coronary and peripheral artery sclerosis, peripheral neuropathies, retinal damage, cataracts, hypertension, coma, and death from hypoglycemic shock.
- the symptoms of the disease can be controlled by administering additional insulin (or other agents that have similar effects) by injection or by external or implantable insulin pumps.
- the "correct” insulin dosage is a function of the level of glucose in the blood. Ideally, insulin administration should be continuously readjusted in response to changes in blood glucose level.
- insulin instructs the body's cells to take in glucose from the blood.
- Glucagon acts opposite to insulin, and causes the liver to release glucose into the blood stream.
- the “basal rate” is the rate of continuous supply of insulin provided by an insulin delivery device (pump).
- the "bolus” is the specific amount of insulin that is given to raise blood concentration of the insulin to an effective level when needed (as opposed to continuous).
- a glucose sensitive probe into the patient.
- Such probes measure various properties of blood or other tissues, including optical absorption, electrochemical potential, and enzymatic products.
- the output of such sensors can be communicated to a hand held device that is used to calculate an appropriate dosage of insulin to be delivered into the blood stream in view of several factors, such as a patient's present glucose level, insulin usage rate, carbohydrates consumed or to be consumed, and exercise, among others. These calculations can then be used to control a pump that delivers the insulin, either at a controlled basal rate, or as a bolus.
- the continuous glucose monitor, controller, and pump work together to provide continuous glucose monitoring and insulin pump control.
- Such systems at present require intervention by a patient to calculate and control the amount of insulin to be delivered.
- a system capable of integrating and automating the functions of glucose monitoring and controlled insulin delivery would be useful in assisting patients in maintaining their glucose levels, especially during periods of the day when they are unable to intervene.
- a closed-loop system also called the “artificial pancreas,” consists of three components: a glucose monitoring device such as a continuous glucose monitor (“CGM”) that measures subcutaneous glucose concentration (“SC”); a titrating algorithm to compute the amount of analyte such as insulin and/or glucagon to be delivered; and one or more analyte pumps to deliver computed analyte doses subcutaneously.
- CGM continuous glucose monitor
- SC subcutaneous glucose concentration
- analyte pumps to deliver computed analyte doses subcutaneously.
- TlDM type 1 diabetes mellitus
- TlDM type 1 diabetes mellitus
- the main reason for gradual deployment is the uncertain risk of hypoglycemia and hyperglycemia, which may arise due to (1) intrinsic overdosing and underdosing of insulin by a control algorithm, and (2) persistent and transient differences between plasma glucose (“PG") and sensor glucose (“SG”).
- PG plasma glucose
- SG sensor glucose
- the transient differences could be either of physiological origin (SC glucose kinetics) or due to a temporal CGM device artifact.
- CE CGM calibration error
- the relatively slow absorption of subcutaneously administered "rapid-acting" insulin analogues and other system imperfections such as pump delivery errors may exacerbate the hypoglycemia and hyperglycemia risks.
- the present invention is directed to a system for the delivery of insulin to a patient, the system comprising a glucose sensor configured to provide a sensor glucose measurement signal representative of sensed glucose, an insulin delivery device configured to deliver insulin to a patient in response to control signals, and a controller programmed to receive the sensor glucose measurement signal and to provide a delivery control signal to the delivery device as a function of the received sensor glucose measurement signal in accordance with a control model and a glucose measurement error model, wherein the glucose measurement error model is derived from actual glucose sensor measurement data.
- the glucose measurement error model is derived solely from actual glucose sensor measurement data. In another aspect, the glucose measurement error model is derived solely from actual glucose sensor error data, excluding sensor noise data. In another aspect, the glucose measurement error model is derived solely from actual glucose sensor measurement data to the exclusion of randomly-generated variable data. In yet a further aspect, the glucose measurement error model is derived solely from a fixed time history of error data from actual use of a glucose sensor of the same type as the sensor of the system. And in yet another aspect, the glucose measurement error model is derived from actual glucose sensor measurement data from a glucose sensor of the same type as the sensor of the system.
- control model comprises a model predictive control and the controller is also programmed to provide the delivery control signals to the delivery device as a function of a model predictive control.
- the glucose measurement error model is derived from calibration error of the glucose sensor, which comprises the difference between a plasma glucose level and the sensor glucose level signal of the glucose sensor. Further, the glucose measurement error model is derived from a glucose sensor dropout reading.
- the controller is further programmed to recalibrate the system when the difference between the received sensor glucose level signal and a plasma glucose level exceeds a predetermined level.
- the delivery control signal is also a function of the weight of a patient, a total daily insulin dose, and a basal insulin profile, and wherein the controller is also programmed to calculate from the control model an accepted value, the controller is also programmed to calculate from the glucose level signal an inferred value, the controller is also programmed to forecast a future plasma glucose level excursion based on the accepted value and inferred value, and the controller is also programmed to adjust the delivery control signal in accordance with the forecast future plasma glucose level excursion.
- the accepted value comprises an insulin sensitivity of the patient, a glucose distribution volume, and an insulin distribution volume
- the inferred value comprises glucose flux and a carbohydrate bioavailability.
- the controller is also programmed to adjust a value of the delivery control signal in accordance with a safety check.
- a safety check comprises at least one of imposing a maximum infusion rate related to a basal rate depending on a current sensor glucose level, time since a previous meal, and carbohydrate content of a meal, shutting off insulin delivery at a predetermined low sensor glucose value, reducing insulin delivery when sensor glucose is decreasing rapidly, and capping the insulin infusion to a preprogrammed basal rate if an insulin delivery pump occlusion is inferred.
- the glucose sensor, the insulin delivery device, and the controller are virtual devices, each being programmed for in silico testing of a system for delivery of insulin to a virtual patient.
- the invention is also directed to a method for delivering insulin to a patient, the method comprising sensing a glucose level and providing a glucose measurement signal representative of the sensed glucose, providing a control signal as a function of the glucose measurement signal in accordance with a control model and a glucose measurement error model, wherein the glucose measurement error model is derived from actual/experimental glucose sensor data, and delivering insulin in response to the control signal.
- providing the control signal further comprises producing the control signal in accordance with a model predictive control.
- the glucose measurement error model used in the method is derived solely from actual glucose sensor measurement data.
- the glucose measurement error model is derived solely from actual glucose sensor error data, excluding sensor noise data.
- the glucose measurement error model is derived solely from actual glucose sensor measurement data to the exclusion of randomly-generated variable data.
- the glucose measurement error model is derived solely from a fixed time history of error data from actual use of a glucose sensor of the same type as the sensor of the system.
- the glucose measurement error model is derived from actual glucose sensor measurement data from a glucose sensor of the same type as the sensor of the system.
- more detailed aspects include determining a calibration error of a glucose sensor from actual sensor data, based on the difference between a plasma glucose level and the glucose level signal and deriving the glucose measurement error model therefrom. Deriving the glucose measurement error model further comprises determining a glucose sensor dropout reading from actual sensor data and deriving the glucose measurement error model therefrom.
- control signal as a function of the weight of a patient, a total daily insulin dose, and a basal insulin profile
- the method further comprising determining, based on the control model, at least one accepted value, calculating from the glucose level signal at least one inferred value, adjusting the control model in accordance with the accepted value and inferred value, and forecasting a future plasma glucose level excursion based on the control model.
- Determining the accepted value comprises basing the determination on an insulin sensitivity of the patient, a glucose distribution volume, and an insulin distribution volume.
- Calculating the inferred value comprises calculating the inferred value also from glucose flux and a carbohydrate bioavailability.
- the method further comprises adjusting a value of the control signal in accordance with a safety check, comprising at least one of imposing a maximum infusion rate related to a basal rate depending on a current sensor glucose level, time since a previous meal, and carbohydrate content of a meal, shutting off insulin delivery at a sensor glucose of 77 mg/dl, reducing insulin delivery when sensor glucose is decreasing rapidly, and capping the insulin infusion to a pre-programmed basal rate if an insulin delivery pump occlusion is inferred.
- a safety check comprising at least one of imposing a maximum infusion rate related to a basal rate depending on a current sensor glucose level, time since a previous meal, and carbohydrate content of a meal, shutting off insulin delivery at a sensor glucose of 77 mg/dl, reducing insulin delivery when sensor glucose is decreasing rapidly, and capping the insulin infusion to a pre-programmed basal rate if an insulin delivery pump occlusion is inferred.
- the sensing, providing a control signal, and delivering insulin are performed virtually, each occurring for in silico testing of a method for delivery of insulin to a virtual patient.
- TABLE 1 provides demographic data of young subjects with type 1 diabetes mellitus participating in studies
- TABLE 3 shows the incidence of hypoglycemia and hyperglycemia per 100 person years during simulated overnight closed-loop studies and during overnight open-loop studies;
- FIG. IA presents a block diagram of a closed-loop insulin infusion system using a model predictive controller
- FIG. IB presents a block diagram of a closed-loop insulin infusion system using a glucose measurement error model in accordance with aspects of the invention
- FIG. 2 shows simulated sensor glucose traces from the four quartiles of dropout severity alongside the underlying plasma glucose trace.
- Ql represents negligible dropouts while Q4 represents the most severe dropouts;
- FIG. 3 provides a protocol of a simulated overnight closed-loop study showing a simulated study of fifteen hours duration, starting at 17:00 and ending at 08:00 the next day;
- FIG. 4 shows a sample simulation of overnight closed-loop control adopting a +20% CGM system calibration error and a dropout trace from quartile two.
- the graph presents plasma glucose, interstitial glucose, sensor glucose, and insulin infusion;
- FIG. 7 presents the incidence of severe hypoglycemia ( ⁇ 36 mg/dl) twenty minutes or shorter and longer than twenty minutes during simulated overnight closed-loop studies as a function of CGM system calibration error.
- 720 simulations were run; the occurrence of one event in 720 simulations corresponds to around fifty events per one-hundred person years;
- FIG. 8 presents the incidence of significant hypoglycemia ( ⁇ 45 mg/dl) sixty minutes or shorter and longer than sixty minutes during simulated overnight closed-loop studies as a function of CGM system calibration error.
- 720 simulations were run; the occurrence of one event in 720 simulations corresponds to around fifty events per one-hundred person years;
- FIG. 9 plots the incidence of significant hyperglycemia (> 300 mg/dl) sixty minutes or shorter and longer than sixty minutes during simulated overnight closed-loop studies as a function of CGM system calibration error.
- 720 simulations were run; the occurrence of one event in 720 simulations corresponds to around fifty events per one-hundred person years; and
- FIG. 10 provides a sample simulation showing hypoglycemia due to prandial insulin overdosing.
- FIG. IA a basic block diagram of a closed-loop system 20 for continuous glucose monitoring and for continuous subcutaneous insulin infusion using a model predictive controller 26.
- the patient receives exogenous inputs, such as meals.
- the patient's glucose is measured 24, evaluated by the model predictive controller (MPC) and is used by the MPC to control a delivery device, such as a pump 28, to deliver medication to the patient to control blood glucose.
- MPC model predictive controller
- a control algorithm was used based on the model predictive control (“MPC”) paradigm 18 to deliver insulin in a closed-loop fashion.
- Interstitial glucose measurement occurs and every fifteen minutes, simulated real-time sensor glucose (“SG") 24 was fed into the MPC controller 26, which calculated subcutaneous glucose concentration (“SC”) insulin infusion for the insulin pump 28.
- SC subcutaneous glucose concentration
- a dose calculator 45 is included in this embodiment.
- the MPC controller 26 adopts a compartment model of glucose kinetics describing the effect of (1) SC rapid-acting insulin analogue and (2) the carbohydrate (“CHO”) content of meals on SG excursions.
- a list of abbreviations used in the specification and drawings and the items they stand for is included at the end of the specification.
- the glucoregulatory model is initialized using a subject's weight, total daily insulin dose, and the basal insulin profile (patient parameters) 40. These values feed into estimates of temporal insulin sensitivity and glucose and insulin distribution volumes.
- Using a Kalman filter 46 approach real-time SG measurements are used to update two model parameters: (1) a glucose flux quantifying model misspecification; and (2) CHO bioavailability.
- Several competing models differing in the rate of SC insulin absorption and action and the CHO absorption profile are run in parallel.
- a computationally efficient, stochastic-based approach is used to derive a combined control model 30 that best explains observed SG excursions.
- the combined control model 30 is used to forecast plasma glucose ("PG") 42 excursions over a two and one-half hour prediction horizon.
- a sequence of standard deviation (“SD”) insulin infusion rates is determined, which approximates the desired PG trajectory, characterized by a slow decline from hyperglycemia and a rapid recovery from hypoglycemia to target glucose, which is set at minimum to 104 mg/dl but is elevated up to 132 mg/dl to take into account inaccuracies of model-based predictions.
- the first infusion rate from the sequence of SC insulin infusion rates is delivered by the insulin pump 28 subject to safety checks 44, which can reduce the infusion rate to prevent insulin overdosing.
- a simulation environment designed to support the development of closed- loop insulin delivery systems was used. 12
- the simulation environment is flexible and allows the following components to be defined: a model of glucose regulation, an experimental protocol, a glucose sensing model, an insulin pump model, and outcome metrics.
- a model of glucose kinetics and insulin action described by Hovorka and colleagues. 14 ' 23 was adopted.
- Other submodels include the model of SC insulin kinetics, the model of gut absorption, and the model of interstitial glucose (IG) kinetics. 23 ' 24
- the simulator includes eighteen synthetic subjects (virtual patients) with TlDM defined by eighteen parameter sets, representing the virtual TlDM population. A subset of parameters were estimated from experimental data collected in subjects with TlDM, 14 and the remaining parameters were drawn from informed probability distributions. 13 ' 23 The inter- subject variability is addressed through assigning a unique set of parameter values to each individual synthetic subject. The subjects vary, for instance, in their insulin sensitivity to glucose distribution, disposal, and endogenous glucose production. 14 ' 23 The virtual subjects are characterized by their daily insulin requirements (0.35 ⁇ 0.14 U/day/kg), insulin-to-CHO ratio (1.7 ⁇ 1.0 U/10 g CHO), and body weight (74.9 ⁇ 14.4 kg).
- Intra-individual variability of the gluco-regulatory system is represented by superimposing oscillations on selected model parameters or adding random inter-occasion variability to parameter values. Sinusoidal oscillations with an amplitude of 5% and a three-hour period were superimposed on nominal values of most model parameters. Each parameter had a different phase generated randomly from a uniform distribution U [0,3 h]. Bioavailability of ingested CHO is characterized by 20% inter-occasion variability.
- the glucose measurement error model 48 was derived from experimental data.
- FSN FreeStyle Navigator ® Continuous Glucose Monitor System
- CE FreeStyle Navigator ® Continuous Glucose Monitor System
- CE FreeStyle Navigator ® Continuous Glucose Monitor System
- CE FreeStyle Navigator ® Continuous Glucose Monitor System
- CE FreeStyle Navigator ® Continuous Glucose Monitor System
- CE FreeStyle Navigator ® Continuous Glucose Monitor System
- D(t) is the dropout trace of the FSN.
- the FreeStyle Navigator® Continuous Glucose Monitor system with TRUstart algorithm (Abbott Diabetes Care, Alameda, CA) was used for the present study.
- the FSN system occasionally exhibits a nonzero-mean signal artifact referred to here as "dropout," where certain mechanical perturbation of the sensor results in a momentarily attenuated glucose concentration.
- Dropouts were quantified using data from a study where fifty-eight living subjects with TlDM had simultaneously worn two sensors over the course of up to five days. 26 Values from the two sensors worn simultaneously on each subject were paired every minute. The point-wise difference between the paired glucose readings was computed. To account for residual CE, a segment's point-wise difference was normalized by subtracting the median bias of the segment.
- FIG. 2 presents simulated sensor glucose traces from the four quartiles of dropout severity alongside the underlying plasma glucose trace.
- the first quartile Ql represents negligible dropouts while the fourth quartile Q4 represents the most servere dropouts.
- CE (SG - IG)/IG. In these simulations, therefore, a +5% CE means that the reported SG value is consistently 1.05 times higher than expected for a given IG concentration.
- the FSN System is designed for five-day wear, with calibrations nominally scheduled at 1, 2, 10, 24, and 72 hours after sensor insertion.
- a morning CGM sensor insertion is assumed for the night-time only closed- loop control.
- each night time, closed-loop session is assumed not to include a scheduled calibration, allowing CE to remain constant for the duration of the night session.
- the sensor data set comprised 248 living subjects with TlDM or type 2 diabetes mellitus ("T2DM") and were a combination of general sensor wear and in-clinic wear that included periods of specific glucose and insulin challenges.
- CE (SG - PG)/PG.
- the CE for a single calibration session was calculated from pairs of SG-reference glucose values where all the SG values were derived from a single calibration and reference glucose used for calibration were excluded from the calculations. Unlike the calculation of dropouts, only reference glucose values measured from finger sticks using the inbuilt blood glucose meter were used. In addition, the real-time calibration of SG values used the FSN system with TRUstart algorithm.
- the simulated study was fifteen hours long, starting at 17:00 and ending at 08:00 the next day.
- Plasma glucose at the start of the simulated study was drawn from a log-normal distribution, with a mean of 126 mg/dl constrained to a range from 72 to 180 mg/dl.
- a meal consisting of 50 g CHO was planned at 18:00 and was accompanied by a prandial insulin bolus.
- the insulin infusion rate between 17:00 and 21:00 was calculated using the simulation model of a particular virtual subject assuming steady-state conditions at the start of the experiment.
- the closed-loop glucose control algorithm took over the insulin delivery.
- the insulin infusion rate was calculated every fifteen minutes on the basis of CGM values, which included the dropout and CE components.
- the simulation studies were run in batches differing by the level of FSN CE. In total, 25 levels of FSN CEs ranging from -80% to +100% were simulated. The range covering 0% to 60% error was subdivided into 5% steps. The remaining range was spaced 10% apart. Each of the eighteen virtual subjects with TlDM was associated with one of forty randomly selected CGM dropout traces (ten traces from each of the four quartiles of increasing severity). This resulted in 720 different combinations and formed a single simulation batch. Each batch was run with all 25 levels of FSN CE, totaling 18,000 simulated overnight studies. Open Loop Studies
- a sampling cannula was inserted in a vein of an arm and kept patent with sodium chloride.
- the subjects ate a self-selected meal (87 ⁇ 23 g CHO) accompanied by prandial insulin (9 ⁇ 5 U; 31% ⁇ 9% of total daily bolus amount) calculated according to the individual insulin-to-CHO ratio and supplemented by correction dose.
- Plasma glucose was determined every fifteen minutes from 17:00 to 08:00 the next day.
- the CSII treatment was optimized by a healthcare professional by retrospectively analyzing seventy-two hours of nonreal-time SG data.
- VO 2 refers to the maximal oxygen uptake, which is widely accepted as a measure of cardiovascular fitness and maximal aerobic power. Continuous recording of VO 2 with breath-by-breath sampling was taken during the treadmill test and for two minutes during recovery after exercise test termination. Heart rate monitoring was maintained. On the study day, the subjects arrived at 15:00 at the Clinical Research Facility. A sampling cannula was inserted and kept patent with sodium chloride.
- subjects had a light meal chosen from a list of standardized snacks (45 ⁇ 13g CHO, 12 ⁇ 3 g fat, 14 ⁇ 4 g protein) accompanied by prandial bolus (4 ⁇ 2 U).
- the subject exercised at 55% VO 2 max on the treadmill from 18:00 until 18:45, with a rest from 18:20 to 18:25.
- basal insulin was left unmodified or was reduced according to individual guidelines.
- the subject's standard insulin pump settings were applied. Plasma glucose was determined every 15 min from 16:00 to 08:00 the next day. If PG dropped below 36 mg/dl, GlucoGel ® (BBI Healthcare, UK) was given and the study night terminated.
- Severe and significant hypoglycemia was declared at PG ⁇ 36 mg/dl (2.0 mmol/liter) and ⁇ 45 mg/dl (2.5 mmol/liter), respectively. These are levels when cognitive behavioral defenses are compromised. 27 Significant hyperglycemia was declared at PG > 300 mg/dl (16.7 mmol/liter).
- the empirical probability distribution function of FSN CE was calculated from the 1421 calibration sessions discussed above. During simulated closed- loop studies, occurrence and duration of hypoglycemia and hyperglycemia based on the simulated PG trace were recorded from 21:00 to 008:00.
- the probability of hypoglycemia and hyperglycemia events occurring overnight at a given FSN CE is obtained as a product of the probability, C 1 , of the given FSN CE and the probability of overnight hypoglycemia and hyperglycemia, h t , at the given FSN CE.
- the overall event probability is obtained as the number of hypoglycemia and hyperglycemia events divided by the number of overnight stays.
- the overall incidence is obtained as reciprocal to the overall event probability.
- FIG. 4 A sample simulation study with +20% FSN CE using dropout trace from quartile two is shown in FIG. 4. Overall, 18,000 simulation studies were performed; 720 simulation studies were run for each of the 25 levels of FSN CE. During simulations, the MPC algorithm was unaware of FSN CE and the extent of the CGM dropout.
- FIG. 5 shows PG and SG values obtained simultaneously during simulation studies at FSN CEs ranging from -80% to +100%.
- increasing levels of FSN CE result in progressively lower median PG.
- the MPC algorithm steps up insulin delivery to limit the increase in SG, unaware of progressively increasing gap between sensor and PG.
- the MPC algorithm performs less efficiently at high FSN CE (see FIG. 6, which plots time-in-target values.)
- the MPC algorithm achieves 60% or higher time-in-target for FSN CE ranging from -20% to +100%.
- FIGS. 7 and 8 show the incidence of severe (PG ⁇ 36 mg/dl) and significant (PG ⁇ 45 mg/dl) hypoglycemia across FSN CE. Severe hypoglycemia did not occur at FSN CE of 40% or lower. Significant hypoglycemia did not occur at FSN CE of 5% or lower.
- TABLE 2 breaks down severe hypoglycemia events according to their duration, providing more detailed information. The longest duration of severe and significant hypoglycemia occurred at the highest 100% FSN CE, lasting for 79 and 178 min, respectively.
- FIG. 9 plots the incidence of significant hyperglycemia (PG > 300 mg/dl) for the different levels of FSN CE.
- Significant hyperglycemia lasting sixty minutes or less was present at most levels of FSN CE, while events lasting more than sixty minutes occurred when FSN CE was below -40%
- the FSN CE probability distribution function is also shown.
- FIG. 7 presents the incidence of severe hypoglycemia ( ⁇ 36 mg/dl) 20 min or shorter and longer than 20 min during simulated overnight closed-loop studies as a function of FSN CE.
- 720 simulations were run; occurrence of one event in 720 simulations corresponds to around 50 events per 100 person years.
- FIG. 8 presents the incidence of significant hypoglycemia ( ⁇ 45 mg/dl) 60 min or shorter and longer than 60 min during simulated overnight closed-loop studies as a function of FSN CE.
- 720 simulations were run; occurrence of one event in 720 simulations corresponds to around 50 events per 100 person years.
- PG at 20:00 was 207 ⁇ 97 mg/dl. Average overnight PG from 20:00 to 08:00 was 146 ⁇ 65 mg/dl. Time spent in the target glucose range from 20:00 to 08:00 was 40% (18-61%) (median [interquartile range]).
- FIG. 9 presents the incidence of significant hyperglycemia (>300 mg/dl) 60 min or shorter and longer than 60 min during simulated overnight closed-loop studies as a function of FSN CE.
- 720 simulations were run; occurrence of one event in 720 simulations corresponds to around 50 events per 100 person years. Discussion
- SG may temporarily drop below the hypoglycemic threshold while PG remains about the threshold.
- the incidence calculations are influenced by three main components: 1) the persistent sensing error, 2) the transient sensing error, and 3) insulin misdosing by the control algorithm.
- the assessment of the first two components is based on large observational data sets, providing solid foundations for the incidence calculations.
- the assessment of the last component is addressed by in silico testing.
- the persistent sensing error poses a greater risk of hypoglycemia than the transient sensing error.
- SG consistently exceed PG levels
- the risk of undetected sustained hypoglycemia increases; for example, a 100% persistent error translates a PG reading of 50 mg/dl into a SG reading of 100 mg/dl.
- the persistent error reflects primarily the SG CE.
- the present study suggests that severe hypoglycemia arises only at an FSN CE of 45% and higher with the study-specific MPC algorithm. This represents 0.845% of the calibration segments.
- the characterization of tails of the distribution of the SG CE is essential for the correct quantification of the hypoglycemia risk, suggesting that risk calculations can only be carried out once large data sets characterizing the performance of any particular CGM system are available.
- transient errors such as dropouts could trigger a momentary reduction or cessation of insulin command due to the perceived hypoglycemia event (present or near future). Such a response might increase the risk of hyperglycemia. Closed-loop systems with a strong predictive and/or derivative term might generate a momentarily exaggerated insulin command when a rapid dropout recovery occurs. If PG is already low, then this transient response could increase the risk of hypoglycemia.
- FIG. 2 Four simulated SG traces with different levels of dropout severity are shown alongside the underlying PG measurements.
- the transient error was obtained by taking the difference of two SG traces and correcting them for CE.
- this approach overestimates the transient error as, by definition, when subtracting two SG traces, the variances of the two transient errors presented in the component SG traces add up.
- a visual inspection of simultaneously observed SG traces in quartiles two to four indicates that the transient error in one of the two SG traces typically dominates, justifying our pragmatic approach, which preserves important characteristics such as dropout clustering.
- the MPC algorithm used in the present study has important in-built safety features. It uses the pre-programmed insulin infusion rate as an initial estimate of the insulin needed to achieve normoglycemia. If SG increases, the MPC algorithm controller steps up insulin delivery but does so cautiously and at the expense of suboptimal SG levels. This is evident in FIGS. 5 and 6, which demonstrate that, with increasing levels of FSN CE, the mean SG concentration increases and the time-in-target assessed with the use of SG decreases. This design feature of the MPC algorithm reduces the impact of FSN CE on the risk of hypoglycemia.
- the simulation study design included a relatively small evening meal compared to the body weight of the virtual subjects. Additionally, pre-meal PG was constrained to levels between 72 and 180 mg/dl. In combination, these two study design aspects limit postprandial hyperglycemia excursions, which are expected to be more pronounced after larger meal sizes and at elevated premeal PG values. Conversely, prandial insulin overdosing due to overestimation of the meal size may result in early postprandial hypoglycemia, which cannot be prevented by closed- loop insulin delivery even if insulin infusion is stopped. Some of the episodes of hypoglycemia observed in the present study were directly attributable to prandial insulin overdosing prior to the start of closed- loop control. An example is shown in FIG.
- hypoglycemia occurred prior to the start of the closed-loop session. Although insulin delivery virtually stopped at the start of closed loop, PG and SG continued to decrease for another thirty minutes. The hypoglycemia event remained undetected, as SG did not reach the hypoglycemia threshold of 63 mg/dl.
- FIG. 10 presents a sample simulation showing hypoglycemia due to prandial insulin overdosing.
- Prandial insulin accompanied the meal at 18:00.
- the closed loop started at 21:00.
- Sensor glucose was obtained using a +30% FSN CE and a dropout trace from quartile two.
- Hypoglycemia occurred before the start of the closed-loop session and continued to worsen for another thirty minutes after the start of closed loop although insulin delivery was virtually turned off.
- Hypoglycemia was undetected, as SG did not reach the hypoglycemia threshold of 63 mg/dl.
- FreeStyle Navigator CE at +30% or higher is estimated to occur 2.5% of the time, assuming no recalibration is performed between scheduled calibrations.
- overnight closed loop using an MPC algorithm and real-time glucose sensing by the FSN system may offer a 200-2300-fold reduction of the hypoglycemia and hyperglycemia incidence. This suggests that existing continuous glucose sensing technologies facilitate safe closed-loop insulin delivery, although confirmation in large clinical studies is required.
- Table 4 includes a list of documents to which reference is made by means of endnotes in the text above. Each of those documents listed in Table 4 is hereby incorporated by reference.
- Plasma glucose per 100 person years (per 100 person years) (per 100 person years)
- Panteleon AE Loutseiko M
- Steil GM Rebrin K. Evaluation of the effect of gain on the meal response of an automated closed-loop insulin delivery system. Diabetes 2006; 55(7):1995-2000.
- Patek SD Bequette BW, Breton M et al. In silico preclinical trials: Methodology and engineering guide to closed-loop control in type 1 diabetes mellitus. J Diabetes Sd Technol 2009; 3(2):269-282.
Abstract
A closed-loop system for insulin infusion overnight uses a model predictive control algorithm ("MPC"). Used with the MPC is a glucose measurement error model which was derived from actual glucose sensor error data. That sensor error data included both a sensor artifacts component, including dropouts, and a persistent error component, including calibration error, all of which was obtained experimentally from living subjects. The MPC algorithm advised on insulin infusion every fifteen minutes. Sensor glucose input to the MPC was obtained by combining model-calculated, noise-free interstitial glucose with experimentally-derived transient and persistent sensor artifacts associated with the FreeStyle Navigator® Continuous Glucose Monitor System ("FSN"). The incidence of severe and significant hypoglycemia reduced 2300- and 200-fold, respectively, during simulated overnight closed-loop control with the MPC algorithm using the glucose measurement error model suggesting that the continuous glucose monitoring technologies facilitate safe closed-loop insulin delivery.
Description
OVERNIGHT CLOSED-LOOP INSULIN DELIVERY WITH MODEL PREDICTIVE CONTROL AND GLUCOSE MEASUREMENT ERROR MODEL
CROSS-REFERENCES TO RELATED APPLICATIONS
This application claims the benefit of U.S. Application No. 61/165,467, filed March 31, 2009; and 61/173,133, filed April 27, 2009; and 61/248,353, filed October 2, 2009, all of which are incorporated by reference in their entirety.
BACKGROUND
The invention is generally directed to an integrated system of blood glucose level detection and use of that information in setting insulin delivery parameters, and more particularly, to the use of actual sensor data in characterizing a sensor for use in performing pre-clinical closed-loop trial studies in silico.
Diabetes is a metabolic disorder that afflicts tens of millions of people throughout the world. Diabetes results from the inability of the body to properly utilize and metabolize carbohydrates, particularly glucose. Normally, the finely-tuned balance between glucose in the blood and glucose in bodily tissue cells is maintained by insulin, a hormone produced by the pancreas which controls, among other things, the transfer of glucose from blood into body tissue cells. Upsetting this balance causes many complications and pathologies including heart disease, coronary and peripheral artery sclerosis, peripheral neuropathies, retinal damage, cataracts, hypertension, coma, and death from hypoglycemic shock.
In patients with insulin-dependent diabetes, the symptoms of the disease can be controlled by administering additional insulin (or other agents that have similar effects) by injection or by external or implantable insulin pumps. The "correct" insulin dosage is a function of the level of glucose in the blood. Ideally, insulin administration should be continuously readjusted in response to changes in blood glucose level. In diabetes management, "insulin" instructs the body's cells to take in glucose from the blood. "Glucagon" acts opposite to insulin, and causes the liver to release glucose into the blood stream. The "basal rate" is the rate of continuous supply of insulin provided by an insulin delivery device (pump). The "bolus" is the specific amount of insulin that is given to raise blood concentration of the insulin to an effective level when needed (as opposed to continuous).
Presently, systems are available for continuously monitoring blood glucose levels by implanting a glucose sensitive probe into the patient. Such probes measure various properties
of blood or other tissues, including optical absorption, electrochemical potential, and enzymatic products. The output of such sensors can be communicated to a hand held device that is used to calculate an appropriate dosage of insulin to be delivered into the blood stream in view of several factors, such as a patient's present glucose level, insulin usage rate, carbohydrates consumed or to be consumed, and exercise, among others. These calculations can then be used to control a pump that delivers the insulin, either at a controlled basal rate, or as a bolus. When provided as an integrated system, the continuous glucose monitor, controller, and pump work together to provide continuous glucose monitoring and insulin pump control.
Such systems at present require intervention by a patient to calculate and control the amount of insulin to be delivered. However, there may be periods when the patient is not able to adjust insulin delivery. For example, when the patient is sleeping, he or she cannot intervene in the delivery of insulin, yet control of a patient's glucose level is still necessary. A system capable of integrating and automating the functions of glucose monitoring and controlled insulin delivery would be useful in assisting patients in maintaining their glucose levels, especially during periods of the day when they are unable to intervene.
Since the year 2000, at least five continuous or semi-continuous glucose monitors have received regulatory approval.1 In combination with continuous subcutaneous insulin infusion ("CSII"),2 these devices have promoted research toward closed-loop systems, which deliver insulin according to real-time needs, as opposed to open-loop systems which lack the real-time responsiveness to changing glucose levels. A closed-loop system, also called the "artificial pancreas," consists of three components: a glucose monitoring device such as a continuous glucose monitor ("CGM") that measures subcutaneous glucose concentration ("SC"); a titrating algorithm to compute the amount of analyte such as insulin and/or glucagon to be delivered; and one or more analyte pumps to deliver computed analyte doses subcutaneously. So far, only a few prototypes have been developed, and testing has been confined to clinical settings.3"8 However, an aggressive concerted effort promises accelerated progress toward home testing of closed- loop systems.
The development, evaluation, and testing of closed- loop systems are time-consuming, costly, and confounded by ethical and regulatory issues. Apart from early stage testing in animals such as the dog9'10 or the swine,11 testing in the computer (virtual) environment, also termed in silico testing, is the only other alternative to evaluate and optimize control algorithms outside human studies. Chassin and colleagues have developed a simulation environment and testing methodology12 using a glucoregulatory model developed in a
multitracer study13 and evaluated a glucose controller developed within the Adicol Project.14 Another simulator has been reported by Cobelli and associates,15 building on model- independent quantification of glucose fluxes occurring during a meal.16 The latter simulator has been accepted by the U.S. Food and Drug Administration to replace animal testing. Patek and coworkers provided guidelines for preclinical testing of control algorithms.17
However, such simulations have used mathematical models of glucose sensors in which random data is used for simulating errors of the sensor. Random number generators are used to simulate random errors of such sensors based on noise of the sensor. Such data are therefore not based on the actual performance of any particular sensor and are likely to have a significant level of inaccuracy.
Closed-loop systems may revolutionize management of type 1 diabetes mellitus ("TlDM"), but their introduction is likely to be gradual, starting from simpler applications such as hypoglycemia prevention or overnight glucose control and progressing to more complex approaches such as twenty-four hours per day/seven days per week (24/7) glucose control.8 The main reason for gradual deployment is the uncertain risk of hypoglycemia and hyperglycemia, which may arise due to (1) intrinsic overdosing and underdosing of insulin by a control algorithm, and (2) persistent and transient differences between plasma glucose ("PG") and sensor glucose ("SG"). The transient differences could be either of physiological origin (SC glucose kinetics) or due to a temporal CGM device artifact. The persistent differences result from the CGM calibration error ("CE"). The relatively slow absorption of subcutaneously administered "rapid-acting" insulin analogues and other system imperfections such as pump delivery errors may exacerbate the hypoglycemia and hyperglycemia risks.
Hence, those of skill in the art have recognized a need for an integrated, automated system combining continuous glucose monitoring and controlled insulin delivery. Such a system would include various features to insure the accuracy of the glucose monitor and to protect the user from either under- or over-dosage of insulin. The system would include various functions for improving the accuracy, usability, control, and safety of the system, including a variety of alarms which could be set by a user or a technician to avoid false alarms while ensuring adequate sensitivity to protect the user. Those skilled in the art have also recognized a need for a more accurate glucose measurement error model for increasing the accuracy of closed- loop systems. The present invention fulfills these, and other needs.
- -
SUMMARY OF THE INVENTION
Briefly and in general terms, the present invention is directed to a system for the delivery of insulin to a patient, the system comprising a glucose sensor configured to provide a sensor glucose measurement signal representative of sensed glucose, an insulin delivery device configured to deliver insulin to a patient in response to control signals, and a controller programmed to receive the sensor glucose measurement signal and to provide a delivery control signal to the delivery device as a function of the received sensor glucose measurement signal in accordance with a control model and a glucose measurement error model, wherein the glucose measurement error model is derived from actual glucose sensor measurement data.
In more detailed aspects, the glucose measurement error model is derived solely from actual glucose sensor measurement data. In another aspect, the glucose measurement error model is derived solely from actual glucose sensor error data, excluding sensor noise data. In another aspect, the glucose measurement error model is derived solely from actual glucose sensor measurement data to the exclusion of randomly-generated variable data. In yet a further aspect, the glucose measurement error model is derived solely from a fixed time history of error data from actual use of a glucose sensor of the same type as the sensor of the system. And in yet another aspect, the glucose measurement error model is derived from actual glucose sensor measurement data from a glucose sensor of the same type as the sensor of the system.
In more detailed aspects, the control model comprises a model predictive control and the controller is also programmed to provide the delivery control signals to the delivery device as a function of a model predictive control. The glucose measurement error model is derived from calibration error of the glucose sensor, which comprises the difference between a plasma glucose level and the sensor glucose level signal of the glucose sensor. Further, the glucose measurement error model is derived from a glucose sensor dropout reading.
In other aspects, the controller is further programmed to recalibrate the system when the difference between the received sensor glucose level signal and a plasma glucose level exceeds a predetermined level. The delivery control signal is also a function of the weight of a patient, a total daily insulin dose, and a basal insulin profile, and wherein the controller is also programmed to calculate from the control model an accepted value, the controller is also programmed to calculate from the glucose level signal an inferred value, the controller is also programmed to forecast a future plasma glucose level excursion based on the accepted value
and inferred value, and the controller is also programmed to adjust the delivery control signal in accordance with the forecast future plasma glucose level excursion. In more detailed aspects, the accepted value comprises an insulin sensitivity of the patient, a glucose distribution volume, and an insulin distribution volume, and the inferred value comprises glucose flux and a carbohydrate bioavailability.
In yet further aspects, the controller is also programmed to adjust a value of the delivery control signal in accordance with a safety check. Such safety check comprises at least one of imposing a maximum infusion rate related to a basal rate depending on a current sensor glucose level, time since a previous meal, and carbohydrate content of a meal, shutting off insulin delivery at a predetermined low sensor glucose value, reducing insulin delivery when sensor glucose is decreasing rapidly, and capping the insulin infusion to a preprogrammed basal rate if an insulin delivery pump occlusion is inferred.
In another aspect, the glucose sensor, the insulin delivery device, and the controller are virtual devices, each being programmed for in silico testing of a system for delivery of insulin to a virtual patient.
The invention is also directed to a method for delivering insulin to a patient, the method comprising sensing a glucose level and providing a glucose measurement signal representative of the sensed glucose, providing a control signal as a function of the glucose measurement signal in accordance with a control model and a glucose measurement error model, wherein the glucose measurement error model is derived from actual/experimental glucose sensor data, and delivering insulin in response to the control signal. In a more detailed aspect, providing the control signal further comprises producing the control signal in accordance with a model predictive control.
In more detailed aspects, the glucose measurement error model used in the method is derived solely from actual glucose sensor measurement data. In another aspect, the glucose measurement error model is derived solely from actual glucose sensor error data, excluding sensor noise data. In another aspect, the glucose measurement error model is derived solely from actual glucose sensor measurement data to the exclusion of randomly-generated variable data. In yet a further aspect, the glucose measurement error model is derived solely from a fixed time history of error data from actual use of a glucose sensor of the same type as the sensor of the system. And in yet another aspect, the glucose measurement error model is derived from actual glucose sensor measurement data from a glucose sensor of the same type as the sensor of the system.
- -
Further, more detailed aspects include determining a calibration error of a glucose sensor from actual sensor data, based on the difference between a plasma glucose level and the glucose level signal and deriving the glucose measurement error model therefrom. Deriving the glucose measurement error model further comprises determining a glucose sensor dropout reading from actual sensor data and deriving the glucose measurement error model therefrom.
Other aspects include providing the control signal as a function of the weight of a patient, a total daily insulin dose, and a basal insulin profile, the method further comprising determining, based on the control model, at least one accepted value, calculating from the glucose level signal at least one inferred value, adjusting the control model in accordance with the accepted value and inferred value, and forecasting a future plasma glucose level excursion based on the control model. Determining the accepted value comprises basing the determination on an insulin sensitivity of the patient, a glucose distribution volume, and an insulin distribution volume. Calculating the inferred value comprises calculating the inferred value also from glucose flux and a carbohydrate bioavailability.
In yet further aspects, the method further comprises adjusting a value of the control signal in accordance with a safety check, comprising at least one of imposing a maximum infusion rate related to a basal rate depending on a current sensor glucose level, time since a previous meal, and carbohydrate content of a meal, shutting off insulin delivery at a sensor glucose of 77 mg/dl, reducing insulin delivery when sensor glucose is decreasing rapidly, and capping the insulin infusion to a pre-programmed basal rate if an insulin delivery pump occlusion is inferred.
In another aspect, the sensing, providing a control signal, and delivering insulin are performed virtually, each occurring for in silico testing of a method for delivery of insulin to a virtual patient.
The features and advantages of the invention will be more readily understood from the following detailed description that should be read in conjunction with the accompanying drawings.
BRIEF DESCRIPTION OF THE TABLES AND DRAWINGS
TABLE 1 provides demographic data of young subjects with type 1 diabetes mellitus participating in studies;
TABLE 2 shows the incidence of severe hypoglycemia per 100 person years during simulated overnight closed- loop studies at increasing levels of CGM system calibration error;
- -
TABLE 3 shows the incidence of hypoglycemia and hyperglycemia per 100 person years during simulated overnight closed-loop studies and during overnight open-loop studies;
FIG. IA presents a block diagram of a closed-loop insulin infusion system using a model predictive controller;
FIG. IB presents a block diagram of a closed-loop insulin infusion system using a glucose measurement error model in accordance with aspects of the invention;
FIG. 2 shows simulated sensor glucose traces from the four quartiles of dropout severity alongside the underlying plasma glucose trace. Ql represents negligible dropouts while Q4 represents the most severe dropouts;
FIG. 3 provides a protocol of a simulated overnight closed-loop study showing a simulated study of fifteen hours duration, starting at 17:00 and ending at 08:00 the next day;
FIG. 4 shows a sample simulation of overnight closed-loop control adopting a +20% CGM system calibration error and a dropout trace from quartile two. The graph presents plasma glucose, interstitial glucose, sensor glucose, and insulin infusion;
FIG. 5 is a graph showing plasma glucose and sensor glucose (median [interquartile range]; N = 720 at each level) during simulated overnight closed- loop studies at different levels of CGM system calibration errors, The CGM system calibration error probability distribution function is also shown;
FIG. 6 is a chart showing time spent in the glucose target range (80 to 145 mg/dl) as quantified using plasma glucose and sensor glucose (medial [interquartile range]; N = 720 at each level) during simulated overnight closed- loop studies at different levels of CGM system calibration error. The CGM system calibration error distribution function is also shown;
FIG. 7 presents the incidence of severe hypoglycemia (<36 mg/dl) twenty minutes or shorter and longer than twenty minutes during simulated overnight closed-loop studies as a function of CGM system calibration error. At each level of CGM system calibration error, 720 simulations were run; the occurrence of one event in 720 simulations corresponds to around fifty events per one-hundred person years;
FIG. 8 presents the incidence of significant hypoglycemia (<45 mg/dl) sixty minutes or shorter and longer than sixty minutes during simulated overnight closed-loop studies as a function of CGM system calibration error. At each level of CGM system calibration error, 720 simulations were run; the occurrence of one event in 720 simulations corresponds to around fifty events per one-hundred person years;
FIG. 9 plots the incidence of significant hyperglycemia (> 300 mg/dl) sixty minutes or shorter and longer than sixty minutes during simulated overnight closed-loop studies as a
function of CGM system calibration error. At each level of CGM system calibration error, 720 simulations were run; the occurrence of one event in 720 simulations corresponds to around fifty events per one-hundred person years; and
FIG. 10 provides a sample simulation showing hypoglycemia due to prandial insulin overdosing.
DETAILED DESCRIPTION OF PREFERRED EMBODIMENTS
Referring now in more detail to the exemplary drawings for purposes of illustrating embodiments of the invention, wherein like reference numerals designate corresponding or like elements among the several views, there is shown in FIG. IA a basic block diagram of a closed-loop system 20 for continuous glucose monitoring and for continuous subcutaneous insulin infusion using a model predictive controller 26. The patient receives exogenous inputs, such as meals. The patient's glucose is measured 24, evaluated by the model predictive controller (MPC) and is used by the MPC to control a delivery device, such as a pump 28, to deliver medication to the patient to control blood glucose.
Glucose Control Algorithm
Referring now to FIG. IB, a control algorithm was used based on the model predictive control ("MPC") paradigm18 to deliver insulin in a closed-loop fashion. Interstitial glucose measurement occurs and every fifteen minutes, simulated real-time sensor glucose ("SG") 24 was fed into the MPC controller 26, which calculated subcutaneous glucose concentration ("SC") insulin infusion for the insulin pump 28. A dose calculator 45 is included in this embodiment. The MPC controller 26 adopts a compartment model of glucose kinetics describing the effect of (1) SC rapid-acting insulin analogue and (2) the carbohydrate ("CHO") content of meals on SG excursions. A list of abbreviations used in the specification and drawings and the items they stand for is included at the end of the specification.
The glucoregulatory model is initialized using a subject's weight, total daily insulin dose, and the basal insulin profile (patient parameters) 40. These values feed into estimates of temporal insulin sensitivity and glucose and insulin distribution volumes. Using a Kalman filter 46 approach, real-time SG measurements are used to update two model parameters: (1) a glucose flux quantifying model misspecification; and (2) CHO bioavailability. Several competing models differing in the rate of SC insulin absorption and action and the CHO absorption profile are run in parallel. A computationally efficient, stochastic-based approach is used to derive a combined control model 30 that best explains observed SG excursions.19
Following estimation of model parameters, the combined control model 30 is used to forecast plasma glucose ("PG") 42 excursions over a two and one-half hour prediction horizon. A sequence of standard deviation ("SD") insulin infusion rates is determined, which approximates the desired PG trajectory, characterized by a slow decline from hyperglycemia and a rapid recovery from hypoglycemia to target glucose, which is set at minimum to 104 mg/dl but is elevated up to 132 mg/dl to take into account inaccuracies of model-based predictions. The first infusion rate from the sequence of SC insulin infusion rates is delivered by the insulin pump 28 subject to safety checks 44, which can reduce the infusion rate to prevent insulin overdosing. These checks include: (1) imposing a maximum infusion rate of two to five times the pre-programmed basal rate, depending on the current SG level, the time since the previous meal(s), and CHO content of meal(s); (2) shutting off insulin delivery at a SG of 77 mg/dl; (3) reducing insulin delivery when SG is decreasing rapidly; and (iv) capping the insulin infusion to the preprogrammed basal rate if a pump occlusion is inferred by the MPC 26.22
For the purposes of the present study, MPC algorithm Version 0.02.02 was used. Earlier versions of the algorithm were used in clinical studies for overnight closed-loop insulin delivery in children and adolescents with TlDM.20"22 Simulation Environment
A simulation environment designed to support the development of closed- loop insulin delivery systems was used.12 The simulation environment is flexible and allows the following components to be defined: a model of glucose regulation, an experimental protocol, a glucose sensing model, an insulin pump model, and outcome metrics. A model of glucose kinetics and insulin action described by Hovorka and colleagues.14'23 was adopted. Other submodels include the model of SC insulin kinetics, the model of gut absorption, and the model of interstitial glucose (IG) kinetics.23'24
The simulator includes eighteen synthetic subjects (virtual patients) with TlDM defined by eighteen parameter sets, representing the virtual TlDM population. A subset of parameters were estimated from experimental data collected in subjects with TlDM,14 and the remaining parameters were drawn from informed probability distributions.13'23 The inter- subject variability is addressed through assigning a unique set of parameter values to each individual synthetic subject. The subjects vary, for instance, in their insulin sensitivity to glucose distribution, disposal, and endogenous glucose production.14'23 The virtual subjects are characterized by their daily insulin requirements (0.35 ± 0.14 U/day/kg), insulin-to-CHO
ratio (1.7 ± 1.0 U/10 g CHO), and body weight (74.9 ± 14.4 kg). Intra-individual variability of the gluco-regulatory system is represented by superimposing oscillations on selected model parameters or adding random inter-occasion variability to parameter values. Sinusoidal oscillations with an amplitude of 5% and a three-hour period were superimposed on nominal values of most model parameters. Each parameter had a different phase generated randomly from a uniform distribution U [0,3 h]. Bioavailability of ingested CHO is characterized by 20% inter-occasion variability.
For the purposes of the present study, the glucose measurement error model 48 was derived from experimental data. The SG concentration was obtained as SG(t) = lG(t) x (1 + CE) + D(/) where IG(O is noise-free interstitial glucose ("IG") concentration calculated by the gluco-regulatory model and normalized such that, at the steady-state, it is identical to PG; CE is FreeStyle Navigator® Continuous Glucose Monitor System ("FSN") calibration error ("CE"), and D(t) is the dropout trace of the FSN. The pump 28 delivery error model was assumed zero mean, uncorrelated, with a constant 5% coefficient of variation for the continuous insulin infusion and the insulin bolus. The simulation environment is implemented in Matlab® (The Mathworks, Natick, MA). FreeStyle Navigator CGM System - Dropouts
The FreeStyle Navigator® Continuous Glucose Monitor system with TRUstart algorithm (Abbott Diabetes Care, Alameda, CA) was used for the present study. The FSN system occasionally exhibits a nonzero-mean signal artifact referred to here as "dropout," where certain mechanical perturbation of the sensor results in a momentarily attenuated glucose concentration.25
Dropouts were quantified using data from a study where fifty-eight living subjects with TlDM had simultaneously worn two sensors over the course of up to five days.26 Values from the two sensors worn simultaneously on each subject were paired every minute. The point-wise difference between the paired glucose readings was computed. To account for residual CE, a segment's point-wise difference was normalized by subtracting the median bias of the segment.
From each pair, only time segments that overlap the night-time period were used, resulting in 285 night time segments. Segments with insufficient data, either due to a sensor starting or sending in the middle of the night time session or due to missing data, were excluded. In total, ninety-one segments were excluded because they contained less than 840
one-minute data points over the 900 minutes night-time session span. As a result, 194 nighttime segments were available for simulation purposes.
The mean absolute difference in each segment was used to quantify dropout severity, and the 194 night-time sessions were separated into four quartiles. Ten dropout segments were chosen randomly from each quartile and used in simulation studies. The simulation environment adds the selected dropout segment onto the modeled IG concentration. Simulated CGM traces incorporating dropout data from each quartile are shown in FIG. 2.
FIG. 2 presents simulated sensor glucose traces from the four quartiles of dropout severity alongside the underlying plasma glucose trace. The first quartile Ql represents negligible dropouts while the fourth quartile Q4 represents the most servere dropouts. FreeStyle Navigator CGM System - Calibration Error
The FreeStyle Navigator System calibration error ("CE") is defined as CE = (SG - IG)/IG. In these simulations, therefore, a +5% CE means that the reported SG value is consistently 1.05 times higher than expected for a given IG concentration.
The FSN System is designed for five-day wear, with calibrations nominally scheduled at 1, 2, 10, 24, and 72 hours after sensor insertion. For the present study, a morning CGM sensor insertion is assumed for the night-time only closed- loop control. Thus, each night time, closed-loop session is assumed not to include a scheduled calibration, allowing CE to remain constant for the duration of the night session.
One-hundred and sixteen (116) insertions used to generate dropout signals in addition to 469 insertions from other studies with living subjects were used to generate a distribution of the FSN CE. The sensor data set comprised 248 living subjects with TlDM or type 2 diabetes mellitus ("T2DM") and were a combination of general sensor wear and in-clinic wear that included periods of specific glucose and insulin challenges.
As IG and PG are assumed to be identical at the steady state, CE can be approximated using an alternative definition: CE = (SG - PG)/PG. The CE for a single calibration session was calculated from pairs of SG-reference glucose values where all the SG values were derived from a single calibration and reference glucose used for calibration were excluded from the calculations. Unlike the calculation of dropouts, only reference glucose values measured from finger sticks using the inbuilt blood glucose meter were used. In addition, the real-time calibration of SG values used the FSN system with TRUstart algorithm.
Excluding calibration sessions containing less than ten SG-reference glucose pairs, 585 insertions yielded 1421 calibration sessions. The CE for each session was computed by
comparing the median value of the relative difference between SG and reference glucose, and 1421 FSN CEs were generated using 35,200 SG-reference glucose pairs, yielding an average of 25 pairs for every calibration session. Protocol of Simulation Studies
As shown in FIG. 3, the simulated study was fifteen hours long, starting at 17:00 and ending at 08:00 the next day. Plasma glucose at the start of the simulated study was drawn from a log-normal distribution, with a mean of 126 mg/dl constrained to a range from 72 to 180 mg/dl. A meal consisting of 50 g CHO was planned at 18:00 and was accompanied by a prandial insulin bolus. The insulin infusion rate between 17:00 and 21:00 was calculated using the simulation model of a particular virtual subject assuming steady-state conditions at the start of the experiment. At 21:00, the closed-loop glucose control algorithm took over the insulin delivery. The insulin infusion rate was calculated every fifteen minutes on the basis of CGM values, which included the dropout and CE components. Closed-loop control continued until the end of the simulated experiment at 08:00. Rescue CHOs (15 g CHO) were administered at SG values 63 mg/dl (3.5 mmol/liter) or below when confirmed by a PG value of 63 mg/dl or below, simulating a confirmatory finger stick glucose measurement. Correction insulin boluses were not administered at hyperglycemia.
The simulation studies were run in batches differing by the level of FSN CE. In total, 25 levels of FSN CEs ranging from -80% to +100% were simulated. The range covering 0% to 60% error was subdivided into 5% steps. The remaining range was spaced 10% apart. Each of the eighteen virtual subjects with TlDM was associated with one of forty randomly selected CGM dropout traces (ten traces from each of the four quartiles of increasing severity). This resulted in 720 different combinations and formed a single simulation batch. Each batch was run with all 25 levels of FSN CE, totaling 18,000 simulated overnight studies. Open Loop Studies
Within the Artificial Pancreas Project at Cambridge ("APCam"), seventeen children and adolescents with TlDM treated by CSII for at least three months participated in the APCamOl study (monitoring study) and APCam03 (exercise study) conducted at the Wellcome Trust Clinical Research Centre, Addenbrooke's Hospital, University of Cambridge, UK. Informed consent was obtained from all study participants or their caregivers. The APCamOl20 and APCamO322 clinical studies were originally designed to compare overnight closed-loop control against the standard CSII treatment. In the present analysis, only results
from the CSII investigations are reported. The study protocols were approved by the Cambridgeshire 3 Ethics Committee. The subjects' demographic data are shown in TABLE 1. Four subjects participated in both studies.
In APCamOl, on subject's arrival at the Clinical Research Facility at 16:00, a sampling cannula was inserted in a vein of an arm and kept patent with sodium chloride. At 18:00, the subjects ate a self-selected meal (87 ± 23 g CHO) accompanied by prandial insulin (9 ± 5 U; 31% ± 9% of total daily bolus amount) calculated according to the individual insulin-to-CHO ratio and supplemented by correction dose. Plasma glucose was determined every fifteen minutes from 17:00 to 08:00 the next day. At least two weeks before the first study, the CSII treatment was optimized by a healthcare professional by retrospectively analyzing seventy-two hours of nonreal-time SG data.
In APCamO3, at least one week before the study, the subjects attended the Clinical Research Facility and a ramped treadmill protocol was used for the estimation of the peak VO2 as an indicator of the maximum exercise effort. As used herein "VO2" refers to the maximal oxygen uptake, which is widely accepted as a measure of cardiovascular fitness and maximal aerobic power. Continuous recording of VO2 with breath-by-breath sampling was taken during the treadmill test and for two minutes during recovery after exercise test termination. Heart rate monitoring was maintained. On the study day, the subjects arrived at 15:00 at the Clinical Research Facility. A sampling cannula was inserted and kept patent with sodium chloride. At 16:00, subjects had a light meal chosen from a list of standardized snacks (45 ± 13g CHO, 12 ± 3 g fat, 14 ± 4 g protein) accompanied by prandial bolus (4 ± 2 U). The subject exercised at 55% VO2 max on the treadmill from 18:00 until 18:45, with a rest from 18:20 to 18:25. During exercise, basal insulin was left unmodified or was reduced according to individual guidelines. During the night, the subject's standard insulin pump settings were applied. Plasma glucose was determined every 15 min from 16:00 to 08:00 the next day. If PG dropped below 36 mg/dl, GlucoGel® (BBI Healthcare, UK) was given and the study night terminated. Data Analysis
Severe and significant hypoglycemia was declared at PG < 36 mg/dl (2.0 mmol/liter) and < 45 mg/dl (2.5 mmol/liter), respectively. These are levels when cognitive behavioral defenses are compromised.27 Significant hyperglycemia was declared at PG > 300 mg/dl (16.7 mmol/liter).
The empirical probability distribution function of FSN CE was calculated from the 1421 calibration sessions discussed above. During simulated closed- loop studies, occurrence and duration of hypoglycemia and hyperglycemia based on the simulated PG trace were recorded from 21:00 to 008:00. The probability of hypoglycemia and hyperglycemia events occurring overnight at a given FSN CE is obtained as a product of the probability, C1, of the given FSN CE and the probability of overnight hypoglycemia and hyperglycemia, ht, at the given FSN CE. The overall event probability P is obtained as the sum of these products over the 25 levels of FSN CE, i.e., P = ∑Cih For APCamOl and APCamO3 studies, the overall event probability is obtained as the number of hypoglycemia and hyperglycemia events divided by the number of overnight stays. The overall incidence is obtained as reciprocal to the overall event probability.
During simulated closed- loop studies, mean PG, mean SG, and time-in-target 80-145 mg/dl were calculated between 20:00 and 08:00 to assess the performance of the MPC algorithm at different levels of FSN CE. Values are shown as mean ± standard deviation unless stated otherwise. Simulated Closed-Loop Studies
A sample simulation study with +20% FSN CE using dropout trace from quartile two is shown in FIG. 4. Overall, 18,000 simulation studies were performed; 720 simulation studies were run for each of the 25 levels of FSN CE. During simulations, the MPC algorithm was unaware of FSN CE and the extent of the CGM dropout.
FIG. 5 shows PG and SG values obtained simultaneously during simulation studies at FSN CEs ranging from -80% to +100%. As expected, increasing levels of FSN CE result in progressively lower median PG. The MPC algorithm steps up insulin delivery to limit the increase in SG, unaware of progressively increasing gap between sensor and PG. Employing the SG values, the MPC algorithm performs less efficiently at high FSN CE (see FIG. 6, which plots time-in-target values.) However, employing the PG values, the MPC algorithm achieves 60% or higher time-in-target for FSN CE ranging from -20% to +100%.
FIGS. 7 and 8 show the incidence of severe (PG < 36 mg/dl) and significant (PG < 45 mg/dl) hypoglycemia across FSN CE. Severe hypoglycemia did not occur at FSN CE of 40% or lower. Significant hypoglycemia did not occur at FSN CE of 5% or lower.
TABLE 2 breaks down severe hypoglycemia events according to their duration, providing more detailed information. The longest duration of severe and significant
hypoglycemia occurred at the highest 100% FSN CE, lasting for 79 and 178 min, respectively.
FIG. 9 plots the incidence of significant hyperglycemia (PG > 300 mg/dl) for the different levels of FSN CE. Significant hyperglycemia lasting sixty minutes or less was present at most levels of FSN CE, while events lasting more than sixty minutes occurred when FSN CE was below -40% The longest duration of significant hyperglycemia occurred at the -80% FSN CE, lasting for 455 minutes. FreeStyle Navigator Calibration Error Distribution
The probability distribution of FSN CE generated from 1421 calibration sessions is shown in FIG. 5 and is replicated in FIG. 6. Approximately three-fourths (%) of the distribution resides within the -10% to +10% range of FSN CE; 35 out of 1421 (2.5% calibration sessions had FSN CE of 30% or higher. Approximately the same number of sessions (37 out of 1421) had a CE of -30% or lower. FIG. 5 presents plasma glucose and SG (median [interquartile range]; N = 720 at each level) during simulated overnight closed- loop studies at different levels of FSN CE. The FSN CE probability distribution function is also shown. FIG. 6 presents time spent in the glucose target range (80 to 145 mg/dl) as quantified using PG and SG (median [interquartile range]; N = 720 at each level) during simulated overnight closed-loop studies at different levels of FSN CE. The FSN CE probability distribution function is also shown.
FIG. 7 presents the incidence of severe hypoglycemia (<36 mg/dl) 20 min or shorter and longer than 20 min during simulated overnight closed-loop studies as a function of FSN CE. At each level of FSN CE, 720 simulations were run; occurrence of one event in 720 simulations corresponds to around 50 events per 100 person years.
FIG. 8 presents the incidence of significant hypoglycemia (<45 mg/dl) 60 min or shorter and longer than 60 min during simulated overnight closed-loop studies as a function of FSN CE. At each level of FSN CE, 720 simulations were run; occurrence of one event in 720 simulations corresponds to around 50 events per 100 person years. Open-Loop Studies
During APCamOl and APCam03 studies, PG at 20:00 was 207 ± 97 mg/dl. Average overnight PG from 20:00 to 08:00 was 146 ± 65 mg/dl. Time spent in the target glucose range from 20:00 to 08:00 was 40% (18-61%) (median [interquartile range]).
During APCam03, one "severe" hypoglycemic event was observed (PG < 36 mg/dl). The subject was given GlucoGel®, and the study night was terminated; thus the duration of
the untreated severe hypoglycemic event cannot be ascertained. Two episodes of "significant" hypoglycemia were observed (PG < 45 mg/dl): one study APCamOl over forty- five minutes in duration and another in APCamO3 over seventy- five minutes in duration, preceding the severe hypoglycemic event above. Overall Incidence of Hypoglycemia and Hyperglycemia
The overall incident of hypoglycemia and hyperglycemia during closed-loop and open- loop studies is shown in TABLE 3.
FIG. 9 presents the incidence of significant hyperglycemia (>300 mg/dl) 60 min or shorter and longer than 60 min during simulated overnight closed-loop studies as a function of FSN CE. At each level of FSN CE, 720 simulations were run; occurrence of one event in 720 simulations corresponds to around 50 events per 100 person years. Discussion
The present study suggests that overnight closed loop combining an MPC algorithm and the FSN CGM system is expected to reduce the risk of hypoglycemia and hyperglycemia compared to the standard CSII therapy. Overnight closed-loop insulin delivery is expected to reduce the incidence of (1) severe hypoglycemia 2300-fold, (2) significant hypoglycemia 200-fold, and (3) significant hyperglycemia 200-fold.
These reductions are indicative rather than conclusive given the differences in subject populations; the lower incidence of hypoglycemia events, particularly those observed clinically during the CSII treatment; and uncertainties associated with in silico testing. It is important to stress that simulated results need to be verified with clinical data and that efforts should be made to assess true hypoglycemia incidence, which may not be indicated by SG traces alone due to the possible presence of the kinds of persistent and transient sensing errors described. In addition, as average SG levels may be reduced during closed-loop insulin delivery compared to the standard CSII treatment, the presence of transient errors due to dropouts may erroneously suggest an increase in hypoglycemic events, i.e., SG may temporarily drop below the hypoglycemic threshold while PG remains about the threshold.
The incidence calculations are influenced by three main components: 1) the persistent sensing error, 2) the transient sensing error, and 3) insulin misdosing by the control algorithm. In the present study, the assessment of the first two components is based on large observational data sets, providing solid foundations for the incidence calculations. The assessment of the last component is addressed by in silico testing. These simulations are the least strong part of our approach due to limitations of the glucose regulation model but
facilitate a rational way to assess performance of a closed-loop system prior to its evaluation in larger clinical studies.
It is argued that the persistent sensing error poses a greater risk of hypoglycemia than the transient sensing error. When SG consistently exceed PG levels, the risk of undetected sustained hypoglycemia increases; for example, a 100% persistent error translates a PG reading of 50 mg/dl into a SG reading of 100 mg/dl. The persistent error reflects primarily the SG CE. The present study suggests that severe hypoglycemia arises only at an FSN CE of 45% and higher with the study-specific MPC algorithm. This represents 0.845% of the calibration segments. Thus the characterization of tails of the distribution of the SG CE is essential for the correct quantification of the hypoglycemia risk, suggesting that risk calculations can only be carried out once large data sets characterizing the performance of any particular CGM system are available.
From a closed- loop control perspective, transient errors such as dropouts could trigger a momentary reduction or cessation of insulin command due to the perceived hypoglycemia event (present or near future). Such a response might increase the risk of hyperglycemia. Closed-loop systems with a strong predictive and/or derivative term might generate a momentarily exaggerated insulin command when a rapid dropout recovery occurs. If PG is already low, then this transient response could increase the risk of hypoglycemia. The effect of dropouts is illustrated in FIG. 2. Four simulated SG traces with different levels of dropout severity are shown alongside the underlying PG measurements.
In the present study, the transient error was obtained by taking the difference of two SG traces and correcting them for CE. Methodologically, this approach overestimates the transient error as, by definition, when subtracting two SG traces, the variances of the two transient errors presented in the component SG traces add up. However, a visual inspection of simultaneously observed SG traces in quartiles two to four indicates that the transient error in one of the two SG traces typically dominates, justifying our pragmatic approach, which preserves important characteristics such as dropout clustering.
Prior investigation of the validity of the predictions made by in silico testing increases the confidence in the incidence calculations. We previously validated the virtual population of 18 subjects with TlDM by simulating a fifteen hour clinical study with an MPC algorithm.28 The protocol of the simulated study reflected the APCamOl study conducted in twelve children and adolescents with TlDM.20 Premeal PG during the simulated study was designed to match that of the real study (177 ± 56 versus 171 ± 67 mg/dl, p = not significant ("NS"); unpaired t test). Sensor glucose at the start of closed-loop control (220 ± 72 versus
191 ± 54 mg/dl, /? = NS) and mean overnight SG (137 ± 22 versus 141 ± 25 mg/dl, /? = NS) were similar during simulated and real studies. Time spent in the target glucose range 80 to 145 mg/dl was not significantly different at 69% (62-78%) versus 63% (49-78%) (median [interquartile range], p = NS). Kovatchev and associates' low blood glucose index [0.5 (0.2- 0.9) versus 0.3 (0.0-1.0),/» = NS] and high blood glucose index [3.4 (1.3-6.8) versus 3.7 (0.6- 6.8), p = NS]29 were also similar during the real and simulated studies, supporting the validity of glucose predictions at low and high glucose levels.
We further assessed the validity of in silico predictions by simulating open- loop studies. First, optimum prandial and optimum basal insulin to achieve and maintain PG at 108 mg/dl were determined for the eighteen virtual subjects during a fifteen hour simulated study commencing at 17:00, with a 50 g CHO meal planned at 18:00. Then basal insulin was increased by 20% and an identical study design was simulated. Additional simulations were performed, with basal insulin increased by 55% and 85%. These increases in the basal insulin delivery corresponded to differences between the average delivered insulin rate and the average insulin rate preprogrammed on the insulin pump during thirty-three overnight closed- loop studies in young people with TlDM treated by CSII.30 In these thirty-three closed-loop studies, a 20% overestimation of basal insulin was observed in three studies, a 55% overestimation in four studies, and an 85% overestimation in one study.
At the 20% overestimation of basal insulin, the simulations yielded no severe hypoglycemia and one significant hypoglycemia in the eighteen virtual subjects. At the 55% overestimation, five and three hypoglycemia events were observed. At the 85% overestimation, eight and two events occurred. This indicates the incidence of severe hypoglycemia during simulated studies at 1720 per 100 person years, which tallies extremely well with a corresponding incidence of 1739 per 100 person years recorded during "true" open loop studies (see Table 3). The incidence of significant hypoglycemia during simulations was 1044 per 100 person years, which is less but still comparable to that observed experimentally at 3479 per 100 person years; the difference in the incidence rates corresponds to two significant hypoglycemia events over thirty-three nights. Overall, these results suggest that in silico simulations provide acceptable predictions of hypoglycemia incidence during open-loop studies, supporting the validity of in silico predictions during closed-loop studies.
The MPC algorithm used in the present study has important in-built safety features. It uses the pre-programmed insulin infusion rate as an initial estimate of the insulin needed to achieve normoglycemia. If SG increases, the MPC algorithm controller steps up insulin
delivery but does so cautiously and at the expense of suboptimal SG levels. This is evident in FIGS. 5 and 6, which demonstrate that, with increasing levels of FSN CE, the mean SG concentration increases and the time-in-target assessed with the use of SG decreases. This design feature of the MPC algorithm reduces the impact of FSN CE on the risk of hypoglycemia.
The simulation study design included a relatively small evening meal compared to the body weight of the virtual subjects. Additionally, pre-meal PG was constrained to levels between 72 and 180 mg/dl. In combination, these two study design aspects limit postprandial hyperglycemia excursions, which are expected to be more pronounced after larger meal sizes and at elevated premeal PG values. Conversely, prandial insulin overdosing due to overestimation of the meal size may result in early postprandial hypoglycemia, which cannot be prevented by closed- loop insulin delivery even if insulin infusion is stopped. Some of the episodes of hypoglycemia observed in the present study were directly attributable to prandial insulin overdosing prior to the start of closed- loop control. An example is shown in FIG. 10, where the insulin overdelivery is confounded by a +30% FSN CE. Hypoglycemia occurred prior to the start of the closed-loop session. Although insulin delivery virtually stopped at the start of closed loop, PG and SG continued to decrease for another thirty minutes. The hypoglycemia event remained undetected, as SG did not reach the hypoglycemia threshold of 63 mg/dl.
The use of CGM alone is expected to reduce the hypoglycemia and hyperglycemia risks as observed in the Juvenile Diabetes Research Foundation CGM trial.31 The observed improvements are clinically important but lack the scale offered by the overnight closed-loop approach. However, even the overnight closed-loop approach, the risk of hypoglycemia and hyperglycemia is not eliminated. The duration of significant and severe hypoglycemia during simulation studies is limited to one and three hours, which is slightly less than the two to four hours of SG-documented hypoglycemia that has been reported prior to seizures.
FIG. 10 presents a sample simulation showing hypoglycemia due to prandial insulin overdosing. Prandial insulin accompanied the meal at 18:00. The closed loop started at 21:00. Sensor glucose was obtained using a +30% FSN CE and a dropout trace from quartile two. Hypoglycemia occurred before the start of the closed-loop session and continued to worsen for another thirty minutes after the start of closed loop although insulin delivery was virtually turned off. Hypoglycemia was undetected, as SG did not reach the hypoglycemia threshold of 63 mg/dl. FreeStyle Navigator CE at +30% or higher is estimated to occur 2.5% of the time, assuming no recalibration is performed between scheduled calibrations.
The FSN CE distribution shown in FIGS. 5 and 6 was constructed assuming that only the five FSN scheduled calibrations are performed. If a manual recalibration was performed to rectify excessive CEs that would have been evident when SG was compared against a finger stick reading, the risk of hypoglycemia and hyperglycemia during overnight closed loop could be further reduced.
More detailed information about transient and persistent sensing errors is required to determine if the present results may be transferable to other commercially available CGM systems.33 Transferability to other control algorithms is uncertain given the wide range of control approaches.
In conclusion, overnight closed loop using an MPC algorithm and real-time glucose sensing by the FSN system may offer a 200-2300-fold reduction of the hypoglycemia and hyperglycemia incidence. This suggests that existing continuous glucose sensing technologies facilitate safe closed-loop insulin delivery, although confirmation in large clinical studies is required.
Abbreviation List:
Table 4 includes a list of documents to which reference is made by means of endnotes in the text above. Each of those documents listed in Table 4 is hereby incorporated by reference.
While the invention has been described in connection with what is presently considered to be the most practical and preferred embodiments, it is to be understood that the invention is not to be limited to the disclosed embodiments and elements, but, to the contrary, is intended to cover various modifications, combinations of features, equivalent arrangements, and equivalent elements included within the spirit and scope of the appended claims.
- -
Study N Gender Age BMI HbAIc Duration of Total daily
(M/F) (years) (kg/m2) (%) diabetes insulin
(years) (U/kg/day)
APCamOI 12 7/5 13.1±4.2 21.9±4.3 8.7±2.0 6.7±4.5 0.89±0.27
APCamO3 9 3/6 14.4±1.8 20.0±2.2 7.8±1.0 5.8±3.0 0.93±0.23
TABLE 1
FSN Calibration Error (%)
Plasma glucose <45 45 50 55 60 70 80 90 100
Any duration 51 51 51 101 152 254 558 1, < 20min 51 * * * * 51 51 «3 20 - 40min * * 51 51 * * 101 304 vι > 40min * * * * * 101 101 101 254
•Severe hypoglycemia event not observed during 720 patient-night simulations for a corresponding level of FSN calibration error; incidence is less than 51 events per 100 person years.
TABLE 2
L/d0 ) mg
Simulated CL OL
Plasma glucose (per 100 person years) (per 100 person years)
Any duration 0.75 1,739f σ> < 20min 0.21 N/A
8 20 - 40min 0.18 N/A
Vl
> 40min 0.36 N/A
Any duration 17.11 3,479
__,
< βOmϊn 15.36 1,739 σ>
60 to 90min 1.07 1,739
LO
Vl 90to120min 0.43
> 120min 0.25 *
Any duration 75.38 15,654
≤ 60min 61.09 10,436
60 to 180 min 5.64 3,479
O Al 180to360min 5.82 1,739
>360min 2.82 *
TABLE 3
TABLE 4
1. Klonoff DC. Continuous Glucose Monitoring: Roadmap for 21 st century diabetes therapy. Diabetes Care 2005; 28(5): 1231 -1239.
2. Pickup JC, Keen H, Parsons JA1 Alberti KG. Continuous subcutaneous insulin infusion: an approach to achieving normoglycaemia. Br Med J 1978; 1(6107):204-207.
3. Hovorka R. Continuous glucose monitoring and closed-loop systems. Diabetic Med 2006; 23(1):1-12.
4. Steil GM, Rebrin K. Closed-loop insulin delivery - what lies between where we are and where we are going? Expert Opin Drug Deliv 2005; 2(2):353-362.
5. Shalitin S1 Phillip M. Closing the loop: combining insulin pumps and glucose sensors in children with type 1 diabetes mellitus. Pediatr Diabetes 2006; 7 Suppl 4:45-49.
6. Re'nard E, Costalat G, Chevassus H, Brϊnger J. Artificial beta-cell: clinical experience toward an implantable closed-loop insulin delivery system. Diabetes Metab 2006; 32(5 Pt 2):497-502.
7. Hovorka R1 Wilinska ME1 Chassin LJ, Dunger DB. Roadmap to the artificial pancreas. Diabetes Res Clin Pract 2006; 74 Suppl 2:S178-S182.
8. Hovorka R. The future of continuous glucose monitoring: closed loop. Curr Diabetes Rev 2008; 4(3):269-279.
9. Panteleon AE, Loutseiko M, Steil GM, Rebrin K. Evaluation of the effect of gain on the meal response of an automated closed-loop insulin delivery system. Diabetes 2006; 55(7):1995-2000.
10. Rebrin K, Fischer U, von Woedtke T, Abel P, Brunstein E. Automated feedback control of subcutaneous glucose concentration in diabetic dogs. Diabetologia 1989; 32{8):573- 576.
11. El-Khatib FH, Jiang J, Damiano ER. Adaptive closed-loop control provides blood- glucose regulation using dual subcutaneous insulin and glucagon infusion in diabetic swine. J Diabetes Sci Technol 2007; 1(2):181-192.
12. Chassin LJ, Wilinska ME, Hovorka R. Evaluation of glucose controllers in virtual environment: Methodology and sample application. Artif lntell Med 2004; 32(3):171- 181.
13. Hovorka R, Shojaee-Moradie F1 Carroll PV et al. Partitioning glucose distribution/transport, disposal, and endogenous production during IVGTT. Am J Physiol 2002; 282:E992-E1007.
14. Hovorka R, Chassin LJ, Wilinska ME et al. Closing the loop: The Adicol experience. Diabetes Technol Ther 2004; 6(3):307-318.
15. DaIIa MC, Raimondo DM, Rizza RA, Cobelli C. GIM, simulation software of meal glucose -- insulin model. J Diabetes ScI Technol 2007; 1(3):323-330.
16. Basu R1 DaIIa Man C, Campioni M et al. Effects of age and sex on postprandial glucose metabolism: differences in glucose turnover, insulin secretion, insulin action, and hepatic Insulin extraction. Diabetes 2006; 55(7):2001-2014.
_ .
17. Patek SD, Bequette BW, Breton M et al. In silico preclinical trials: Methodology and engineering guide to closed-loop control in type 1 diabetes mellitus. J Diabetes Sd Technol 2009; 3(2):269-282.
18. Bequette BW. A critical assessment of algorithms and challenges in the development of a closed-loop artificial pancreas. Diabetes Technol Ther 2005; 7(1):28-47.
19. Mazor E, Averbuch A, Bar-Shalom Y, Dayan J. Interacting multiple model methods in target tracking: A survey, leee Transactions on Aerospace and Electronic Systems 1998; 34(1):103-123.
20. Hovorka R, Acerini CL, Allen J et al. Overnight sc-sc closed-loop control improves glucose control and reduces risk of hypoglycaemia in children and adolescents with type 1 diabetes. Diabetes 2008; 57 (Suppl 1):A22.
21. Hovorka R, Acerini CL, Allen J et al. Good overnight closed-loop glucose control in children and adolescents with type 1 diabetes following ingestion of large, rapidly and slowly absorbed evening meat. Diabetologia 2008; 51 (Suppl 1):181.
22. Hovorka R1 Acerini CL, Allen JM et al. Overnight closed-loop delivery following afternoon exercise in adolescents with type 1 diabetes (T1D). http://www.sessionp>an. com/attd2009 (accessed 7 Mar 2009).
23. Hovorka R, Canonico V, Chassin LJ et al. Non-linear model predictive control of glucose concentration in subjects with type 1 diabetes. Physiol Meas 2004; 25(4):905- 920.
24. Wilinska ME, Chassin LJ, Schaller HC, Schaupp L, Pieber TR, Hovorka R. Insulin kinetics in type-1 diabetes: Continuous and bolus delivery of rapid acting insulin. IEEE Trans Biomed Eng 2005; 52(1):3-12.
25. McGarraugh G, Bergenstal R. Detection of hypoglycemia with continuous interstitial and traditional blood glucose monitoring using the freestyle navigator continuous glucose monitoring system. Diabetes Technol Ther 2009; 11 (3): 145-150.
26. Weinstein RL, Schwartz SL, Brazg RL1 Bugler JR, Peyser TA1 McGarraugh GV. Accuracy of the 5-day FreeStyle Navigator Continuous Glucose Monitoring System: comparison with frequent laboratory reference measurements. Diabetes Care 2007; 30(5):1125-1130.
27. Cryer PE. The barrier of hypoglycemia in diabetes. Diabetes 2008; 57(12):3169-3176.
28. Wilinska ME, Acerini CL, Allen JM1 Chassin LJ, Dunger DB, Hovorka R. Validation of simulation environment utilising clinical data collected during overnight closed-loop glucose control in children and adolescents with type 1 diabetes. Diabetes Technology Meeting, Washington DC 2008.
29. Kovatchev BP, Cox DJ, Gonder-Frederick LA1 Young-Hyman D, Schlundt D, Clarke W. Assessment of risk for severe hypoglycemia among adults with IDDM: validation of the low blood glucose index. Diabetes Care 1998; 21(11):1870-1875.
30. Tamboriaπe WV, Beck RW, Bode BW et al. Continuous glucose monitoring and intensive treatment of type 1 diabetes. N Engl J Med 2008; 359(14):1464-1476.
31. Buckingham B, Wilson DM, Lecher T1 Hanas R, Kaiserman K, Cameron F. Duration of nocturnal hypoglycemia before seizures. Diabetes Care 2008; 31(11):2110-2112.
2. Kovatchev B1 Anderson S, Helnemann L1 Clarke W. Comparison of the numerical and clinical accuracy of four continuous glucose monitors. Diabetes Care 2008; 31(6):1160- 1164.
LABLE 4 (CONTINUED)
Claims
1. A system for the delivery of insulin to a patient, the system comprising: a glucose sensor configured to provide a sensor glucose measurement signal representative of sensed glucose; an insulin delivery device configured to deliver insulin to a patient in response to control signals; and a controller programmed to receive the sensor glucose measurement signal and to provide a delivery control signal to the delivery device as a function of the received sensor glucose measurement signal in accordance with a control model and a glucose measurement error model; wherein the glucose measurement error model is derived from actual glucose sensor measurement data.
2. The system for the delivery of insulin of claim 1, wherein the glucose measurement error model is derived solely from actual glucose sensor measurement data.
3. The system for the delivery of insulin of claim 1, wherein the glucose measurement error model is derived solely from actual glucose sensor error data, excluding sensor noise data.
4. The system for the delivery of insulin of claim 1, wherein the glucose measurement error model is derived solely from actual glucose sensor measurement data to the exclusion of randomly- generated variable data.
5. The system for the delivery of insulin of claim 1, wherein the glucose measurement error model is derived solely from a fixed time history of error data from actual use of a glucose sensor of the same type as the sensor of the system.
6. The system for the delivery of insulin of claim 1, wherein the glucose measurement error model is derived from actual glucose sensor measurement data from a glucose sensor of the same type as the sensor of the system.
7. The system for the delivery of insulin of claim 1, wherein the glucose measurement error model is derived solely from a fixed time history of error data from actual use of a glucose sensor of the same type as the sensor of the system, to the exclusion of randomly-generated variable data and to the exclusion of sensor noise data.
8. The system for the delivery of insulin of claim 1, wherein the control model comprises a model predictive controller that is programmed to provide the delivery control signals to the delivery device as a function of a model predictive control.
9. The system for the delivery of insulin of claim 1, wherein the glucose measurement error model is derived from calibration error of the glucose sensor.
10. The system for the delivery of insulin of claim 9, wherein the calibration error in the glucose measurement error model comprises the difference between a plasma glucose level and the sensor glucose level signal of the glucose sensor.
11. The system for delivering insulin of claim 1, wherein the glucose measurement error model is derived from a glucose sensor dropout.
12. The system for the delivery of insulin of claim 10, wherein the controller is further programmed to recalibrate the system when the difference between the received sensor glucose level signal and a plasma glucose level exceeds a predetermined level.
13. The system for delivering insulin of claim 1, wherein the delivery control signal is also a function of weight of a patient, a total daily insulin dose, and a basal insulin profile, and wherein: the controller is also programmed to calculate from the control model an accepted value; the controller is also programmed to calculate from the glucose level signal an inferred value; the controller is also programmed to forecast a future plasma glucose level excursion based on the accepted value and inferred value; and the controller is also programmed to adjust the delivery control signal in accordance with the forecast future plasma glucose level excursion.
14. The system for delivering insulin of claim 13, wherein the accepted value comprises an insulin sensitivity of the patient, a glucose distribution volume, and an insulin distribution volume.
15. The system for delivering insulin of claim 13, wherein the inferred value comprises glucose flux and a carbohydrate bioavailability.
16. The system for delivering insulin of claim 1, wherein the controller is also programmed to adjust a value of the delivery control signal in accordance with a safety check.
17. The system for delivering insulin of claim 16, wherein the controller is also programmed to adjust a value of the delivery control signal in accordance with the safety check to include at least one of: imposing a maximum infusion rate related to a basal rate depending on a current sensor glucose level, time since a previous meal, and carbohydrate content of a meal; shutting off insulin delivery at a predetermined low sensor glucose value; reducing insulin delivery when sensor glucose is decreasing rapidly; and capping the insulin infusion to a pre-programmed basal rate if an insulin delivery pump occlusion is inferred.
18. The system for delivering insulin of claim 1, wherein the glucose sensor, the insulin delivery device, and the controller are virtual devices, each being programmed for in silico testing of a system for delivery of insulin to a virtual patient.
19. A method for delivering insulin to a patient, the method comprising: sensing a glucose level and providing a glucose measurement signal representative of the sensed glucose; providing a control signal as a function of the glucose measurement signal in accordance with a control model and a glucose measurement error model, wherein the glucose measurement error model is derived from actual glucose sensor measurement data; and delivering insulin in response to the control signal.
20. The method for delivering insulin of claim 19, wherein the glucose measurement error model is derived solely from actual glucose sensor measurement data
21. The method for delivering insulin of claim 19, wherein the glucose measurement error model is derived solely from actual glucose sensor error data, excluding sensor noise data.
22. The method for delivering insulin of claim 19, wherein the glucose measurement error model is derived solely from actual glucose sensor measurement data to the exclusion of randomly-generated variable data.
23. The method for delivering insulin of claim 19, wherein the glucose measurement error model is derived solely from a fixed time history of error data from actual use of a glucose sensor of the same type as the sensor of the system.
24. The method for delivering insulin of claim 19, wherein the glucose measurement error model is derived from actual glucose sensor measurement data from a glucose sensor of the same type as the sensor of the system.
25. The method for delivering insulin of claim 19, wherein the glucose measurement error model is derived solely from a fixed time history of error data from actual use of a glucose sensor of the same type as the sensor of the system, to the exclusion of randomly-generated variable data and to the exclusion of sensor noise data.
26. The method for delivering insulin of claim 19, wherein providing the control signal further comprises producing the control signal in accordance with a model predictive control.
27. The method for delivering insulin of claim 19, further comprising determining a calibration error of a glucose sensor from actual sensor data and deriving the glucose measurement error model therefrom.
28. The method for delivering insulin of claim 27, wherein determining a calibration error comprises determining calibration error based on the difference between a plasma glucose level and the glucose level signal.
29. The method for delivering insulin of claim 19, further comprising determining a glucose sensor dropout reading from actual sensor data and deriving the glucose measurement error model therefrom.
30. The method for delivering insulin of claim 19, wherein providing the control signal is also a function of weight of a patient, a total daily insulin dose, and a basal insulin profile, the method further comprising: determining, based on the control model, at least one accepted value; calculating from the glucose level signal at least one inferred value; adjusting the control model in accordance with the accepted value and inferred value; and forecasting a future plasma glucose level excursion based on the control model.
31. The method for delivering insulin of claim 30, wherein determining the accepted value comprises basing the determination on an insulin sensitivity of the patient, a glucose distribution volume, and an insulin distribution volume.
32. The method for delivering insulin of claim 30, wherein calculating the inferred value comprises calculating the inferred value also from glucose flux and a carbohydrate bioavailability.
33. The method for delivering insulin of claim 19, further comprising adjusting a value of the control signal in accordance with a safety check.
34. The method for delivering insulin of claim 33 wherein adjusting a value of the control signal comprises at least one of: imposing a maximum infusion rate related to a basal rate depending on a current sensor glucose level, time since a previous meal, and carbohydrate content of a meal; shutting off insulin delivery at a predetermined low sensor glucose value; reducing insulin delivery when sensor glucose is decreasing rapidly; and capping the insulin infusion to a pre-programmed basal rate if an insulin delivery pump occlusion is inferred.
35. The method for delivering insulin of claim 19, wherein sensing, providing a control signal, and delivering insulin are performed virtually, each occurring for in silico testing of a method for delivery of insulin to a virtual patient.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP10711525.5A EP2413781B1 (en) | 2009-03-31 | 2010-03-31 | Overnight closed-loop insulin delivery with model predictive control and glucose measurement error model |
Applications Claiming Priority (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US16546709P | 2009-03-31 | 2009-03-31 | |
US61/165,467 | 2009-03-31 | ||
US17313309P | 2009-04-27 | 2009-04-27 | |
US61/173,133 | 2009-04-27 | ||
US24835309P | 2009-10-02 | 2009-10-02 | |
US61/248,353 | 2009-10-02 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2010114929A1 true WO2010114929A1 (en) | 2010-10-07 |
Family
ID=42199975
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2010/029492 WO2010114929A1 (en) | 2009-03-31 | 2010-03-31 | Overnight closed-loop insulin delivery with model predictive control and glucose measurement error model |
Country Status (3)
Country | Link |
---|---|
US (6) | US8062249B2 (en) |
EP (1) | EP2413781B1 (en) |
WO (1) | WO2010114929A1 (en) |
Cited By (49)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2473845A1 (en) * | 2009-09-02 | 2012-07-11 | University Of Virginia Patent Foundation | Tracking the probability for imminent hypoglycemia in diabetes from self-monitoring blood glucose (smbg) data |
CN105079909A (en) * | 2014-05-06 | 2015-11-25 | 成都成电医星数字健康软件有限公司 | Infusion parameter calculating device and system |
EP2943150A4 (en) * | 2013-01-14 | 2016-10-26 | Univ California | Daily periodic target-zone modulation in the model predictive control problem for artificial pancreas for type i diabetes applications |
CN106714874A (en) * | 2014-08-06 | 2017-05-24 | 加利福尼亚大学董事会 | Moving-horizon state-initializer for control applications |
US9724470B2 (en) | 2014-06-16 | 2017-08-08 | Icu Medical, Inc. | System for monitoring and delivering medication to a patient and method of using the same to minimize the risks associated with automated therapy |
CN107530032A (en) * | 2015-04-29 | 2018-01-02 | 比格福特生物医学有限公司 | Operate infusion pump systems |
US9971871B2 (en) | 2011-10-21 | 2018-05-15 | Icu Medical, Inc. | Medical device update system |
US9995611B2 (en) | 2012-03-30 | 2018-06-12 | Icu Medical, Inc. | Air detection system and method for detecting air in a pump of an infusion system |
US10022498B2 (en) | 2011-12-16 | 2018-07-17 | Icu Medical, Inc. | System for monitoring and delivering medication to a patient and method of using the same to minimize the risks associated with automated therapy |
US10042986B2 (en) | 2013-11-19 | 2018-08-07 | Icu Medical, Inc. | Infusion pump automation system and method |
US10046112B2 (en) | 2013-05-24 | 2018-08-14 | Icu Medical, Inc. | Multi-sensor infusion system for detecting air or an occlusion in the infusion system |
US10166328B2 (en) | 2013-05-29 | 2019-01-01 | Icu Medical, Inc. | Infusion system which utilizes one or more sensors and additional information to make an air determination regarding the infusion system |
US10238799B2 (en) | 2014-09-15 | 2019-03-26 | Icu Medical, Inc. | Matching delayed infusion auto-programs with manually entered infusion programs |
US10242060B2 (en) | 2006-10-16 | 2019-03-26 | Icu Medical, Inc. | System and method for comparing and utilizing activity information and configuration information from multiple medical device management systems |
US10238801B2 (en) | 2009-04-17 | 2019-03-26 | Icu Medical, Inc. | System and method for configuring a rule set for medical event management and responses |
US10311972B2 (en) | 2013-11-11 | 2019-06-04 | Icu Medical, Inc. | Medical device system performance index |
US10333843B2 (en) | 2013-03-06 | 2019-06-25 | Icu Medical, Inc. | Medical device communication method |
US10335075B2 (en) | 2013-03-14 | 2019-07-02 | Dexcom, Inc. | Advanced calibration for analyte sensors |
US10342917B2 (en) | 2014-02-28 | 2019-07-09 | Icu Medical, Inc. | Infusion system and method which utilizes dual wavelength optical air-in-line detection |
WO2019143741A1 (en) * | 2018-01-16 | 2019-07-25 | The Regents Of The University Of California | Systems, devices and methods for estimating blood glucose concentrations from signals of sensors deployed in tissue |
US10430761B2 (en) | 2011-08-19 | 2019-10-01 | Icu Medical, Inc. | Systems and methods for a graphical interface including a graphical representation of medical data |
US10434246B2 (en) | 2003-10-07 | 2019-10-08 | Icu Medical, Inc. | Medication management system |
US10463788B2 (en) | 2012-07-31 | 2019-11-05 | Icu Medical, Inc. | Patient care system for critical medications |
US10596316B2 (en) | 2013-05-29 | 2020-03-24 | Icu Medical, Inc. | Infusion system and method of use which prevents over-saturation of an analog-to-digital converter |
US10635784B2 (en) | 2007-12-18 | 2020-04-28 | Icu Medical, Inc. | User interface improvements for medical devices |
US10656894B2 (en) | 2017-12-27 | 2020-05-19 | Icu Medical, Inc. | Synchronized display of screen content on networked devices |
US10692595B2 (en) | 2018-07-26 | 2020-06-23 | Icu Medical, Inc. | Drug library dynamic version management |
US10741280B2 (en) | 2018-07-17 | 2020-08-11 | Icu Medical, Inc. | Tagging pump messages with identifiers that facilitate restructuring |
US10765799B2 (en) | 2013-09-20 | 2020-09-08 | Icu Medical, Inc. | Fail-safe drug infusion therapy system |
US10850024B2 (en) | 2015-03-02 | 2020-12-01 | Icu Medical, Inc. | Infusion system, device, and method having advanced infusion features |
US10861592B2 (en) | 2018-07-17 | 2020-12-08 | Icu Medical, Inc. | Reducing infusion pump network congestion by staggering updates |
US10898641B2 (en) | 2014-04-30 | 2021-01-26 | Icu Medical, Inc. | Patient care system with conditional alarm forwarding |
WO2021108431A1 (en) * | 2019-11-25 | 2021-06-03 | Abbott Diabetes Care Inc. | Methods, devices, and systems for physiological parameter analysis |
US11135360B1 (en) | 2020-12-07 | 2021-10-05 | Icu Medical, Inc. | Concurrent infusion with common line auto flush |
US11235100B2 (en) | 2003-11-13 | 2022-02-01 | Icu Medical, Inc. | System for maintaining drug information and communicating with medication delivery devices |
US11246985B2 (en) | 2016-05-13 | 2022-02-15 | Icu Medical, Inc. | Infusion pump system and method with common line auto flush |
US11278671B2 (en) | 2019-12-04 | 2022-03-22 | Icu Medical, Inc. | Infusion pump with safety sequence keypad |
US11309070B2 (en) | 2018-07-26 | 2022-04-19 | Icu Medical, Inc. | Drug library manager with customized worksheets |
US11324888B2 (en) | 2016-06-10 | 2022-05-10 | Icu Medical, Inc. | Acoustic flow sensor for continuous medication flow measurements and feedback control of infusion |
US11328804B2 (en) | 2018-07-17 | 2022-05-10 | Icu Medical, Inc. | Health checks for infusion pump communications systems |
US11344668B2 (en) | 2014-12-19 | 2022-05-31 | Icu Medical, Inc. | Infusion system with concurrent TPN/insulin infusion |
US11344673B2 (en) | 2014-05-29 | 2022-05-31 | Icu Medical, Inc. | Infusion system and pump with configurable closed loop delivery rate catch-up |
EP4116986A1 (en) * | 2021-07-07 | 2023-01-11 | Fresenius Medical Care Deutschland GmbH | Systems and methods for optimization of disease therapy |
US11574737B2 (en) | 2016-07-14 | 2023-02-07 | Icu Medical, Inc. | Multi-communication path selection and security system for a medical device |
US11571508B2 (en) | 2013-08-30 | 2023-02-07 | Icu Medical, Inc. | System and method of monitoring and managing a remote infusion regimen |
US11587669B2 (en) | 2018-07-17 | 2023-02-21 | Icu Medical, Inc. | Passing authentication token to authorize access to rest calls via web sockets |
US11605468B2 (en) | 2015-05-26 | 2023-03-14 | Icu Medical, Inc. | Infusion pump system and method with multiple drug library editor source capability |
US11883361B2 (en) | 2020-07-21 | 2024-01-30 | Icu Medical, Inc. | Fluid transfer devices and methods of use |
US11972395B2 (en) | 2023-02-01 | 2024-04-30 | Icu Medical, Inc. | Systems and methods for a graphical interface including a graphical representation of medical data |
Families Citing this family (95)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20190357827A1 (en) | 2003-08-01 | 2019-11-28 | Dexcom, Inc. | Analyte sensor |
US20100331646A1 (en) * | 2009-06-30 | 2010-12-30 | Abbott Diabetes Care Inc. | Health Management Devices and Methods |
US9636450B2 (en) | 2007-02-19 | 2017-05-02 | Udo Hoss | Pump system modular components for delivering medication and analyte sensing at seperate insertion sites |
US20080314395A1 (en) | 2005-08-31 | 2008-12-25 | Theuniversity Of Virginia Patent Foundation | Accuracy of Continuous Glucose Sensors |
US8880138B2 (en) | 2005-09-30 | 2014-11-04 | Abbott Diabetes Care Inc. | Device for channeling fluid and methods of use |
US7885698B2 (en) | 2006-02-28 | 2011-02-08 | Abbott Diabetes Care Inc. | Method and system for providing continuous calibration of implantable analyte sensors |
US7826879B2 (en) | 2006-02-28 | 2010-11-02 | Abbott Diabetes Care Inc. | Analyte sensors and methods of use |
US7630748B2 (en) | 2006-10-25 | 2009-12-08 | Abbott Diabetes Care Inc. | Method and system for providing analyte monitoring |
US9675290B2 (en) | 2012-10-30 | 2017-06-13 | Abbott Diabetes Care Inc. | Sensitivity calibration of in vivo sensors used to measure analyte concentration |
US8219173B2 (en) | 2008-09-30 | 2012-07-10 | Abbott Diabetes Care Inc. | Optimizing analyte sensor calibration |
US9392969B2 (en) | 2008-08-31 | 2016-07-19 | Abbott Diabetes Care Inc. | Closed loop control and signal attenuation detection |
US8224415B2 (en) | 2009-01-29 | 2012-07-17 | Abbott Diabetes Care Inc. | Method and device for providing offset model based calibration for analyte sensor |
US8135548B2 (en) | 2006-10-26 | 2012-03-13 | Abbott Diabetes Care Inc. | Method, system and computer program product for real-time detection of sensitivity decline in analyte sensors |
US8930203B2 (en) | 2007-02-18 | 2015-01-06 | Abbott Diabetes Care Inc. | Multi-function analyte test device and methods therefor |
US20080228056A1 (en) | 2007-03-13 | 2008-09-18 | Michael Blomquist | Basal rate testing using frequent blood glucose input |
US7751907B2 (en) | 2007-05-24 | 2010-07-06 | Smiths Medical Asd, Inc. | Expert system for insulin pump therapy |
US8221345B2 (en) | 2007-05-30 | 2012-07-17 | Smiths Medical Asd, Inc. | Insulin pump based expert system |
US8160900B2 (en) | 2007-06-29 | 2012-04-17 | Abbott Diabetes Care Inc. | Analyte monitoring and management device and method to analyze the frequency of user interaction with the device |
US20090164239A1 (en) | 2007-12-19 | 2009-06-25 | Abbott Diabetes Care, Inc. | Dynamic Display Of Glucose Information |
US20090177147A1 (en) | 2008-01-07 | 2009-07-09 | Michael Blomquist | Insulin pump with insulin therapy coaching |
US8924159B2 (en) | 2008-05-30 | 2014-12-30 | Abbott Diabetes Care Inc. | Method and apparatus for providing glycemic control |
US8591410B2 (en) | 2008-05-30 | 2013-11-26 | Abbott Diabetes Care Inc. | Method and apparatus for providing glycemic control |
WO2010009172A1 (en) | 2008-07-14 | 2010-01-21 | Abbott Diabetes Care Inc. | Closed loop control system interface and methods |
US7959598B2 (en) | 2008-08-20 | 2011-06-14 | Asante Solutions, Inc. | Infusion pump systems and methods |
US9326707B2 (en) | 2008-11-10 | 2016-05-03 | Abbott Diabetes Care Inc. | Alarm characterization for analyte monitoring devices and systems |
US8103456B2 (en) | 2009-01-29 | 2012-01-24 | Abbott Diabetes Care Inc. | Method and device for early signal attenuation detection using blood glucose measurements |
US8062249B2 (en) * | 2009-03-31 | 2011-11-22 | Abbott Diabetes Care Inc. | Overnight closed-loop insulin delivery with model predictive control and glucose measurement error model |
EP2419015A4 (en) * | 2009-04-16 | 2014-08-20 | Abbott Diabetes Care Inc | Analyte sensor calibration management |
EP2432377A1 (en) | 2009-05-22 | 2012-03-28 | Abbott Diabetes Care, Inc. | Usability features for integrated insulin delivery system |
DK3689237T3 (en) | 2009-07-23 | 2021-08-16 | Abbott Diabetes Care Inc | Method of preparation and system for continuous analyte measurement |
CA2769030C (en) | 2009-07-30 | 2016-05-10 | Tandem Diabetes Care, Inc. | Infusion pump system with disposable cartridge having pressure venting and pressure feedback |
US9320461B2 (en) | 2009-09-29 | 2016-04-26 | Abbott Diabetes Care Inc. | Method and apparatus for providing notification function in analyte monitoring systems |
WO2011053881A1 (en) | 2009-10-30 | 2011-05-05 | Abbott Diabetes Care Inc. | Method and apparatus for detecting false hypoglycemic conditions |
US8882701B2 (en) | 2009-12-04 | 2014-11-11 | Smiths Medical Asd, Inc. | Advanced step therapy delivery for an ambulatory infusion pump and system |
WO2011112753A1 (en) | 2010-03-10 | 2011-09-15 | Abbott Diabetes Care Inc. | Systems, devices and methods for managing glucose levels |
US8635046B2 (en) | 2010-06-23 | 2014-01-21 | Abbott Diabetes Care Inc. | Method and system for evaluating analyte sensor response characteristics |
US10092229B2 (en) | 2010-06-29 | 2018-10-09 | Abbott Diabetes Care Inc. | Calibration of analyte measurement system |
WO2012142502A2 (en) | 2011-04-15 | 2012-10-18 | Dexcom Inc. | Advanced analyte sensor calibration and error detection |
US9940440B2 (en) | 2011-04-28 | 2018-04-10 | Medtronic, Inc. | Detecting and responding to software and hardware anomalies in a fluid delivery system |
WO2013066849A1 (en) | 2011-10-31 | 2013-05-10 | Abbott Diabetes Care Inc. | Model based variable risk false glucose threshold alarm prevention mechanism |
WO2013074289A2 (en) * | 2011-10-31 | 2013-05-23 | Abbott Diabetes Care Inc. | Determination of glucose testing schedule |
US9180242B2 (en) | 2012-05-17 | 2015-11-10 | Tandem Diabetes Care, Inc. | Methods and devices for multiple fluid transfer |
US9238100B2 (en) | 2012-06-07 | 2016-01-19 | Tandem Diabetes Care, Inc. | Device and method for training users of ambulatory medical devices |
EP2901153A4 (en) | 2012-09-26 | 2016-04-27 | Abbott Diabetes Care Inc | Method and apparatus for improving lag correction during in vivo measurement of analyte concentration with analyte concentration variability and range data |
US10357606B2 (en) | 2013-03-13 | 2019-07-23 | Tandem Diabetes Care, Inc. | System and method for integration of insulin pumps and continuous glucose monitoring |
US10201656B2 (en) | 2013-03-13 | 2019-02-12 | Tandem Diabetes Care, Inc. | Simplified insulin pump for type II diabetics |
US9173998B2 (en) | 2013-03-14 | 2015-11-03 | Tandem Diabetes Care, Inc. | System and method for detecting occlusions in an infusion pump |
US20160038673A1 (en) | 2013-03-15 | 2016-02-11 | Animas Corporation | Insulin time-action model |
US9517306B2 (en) | 2013-03-15 | 2016-12-13 | Animas Corporation | Method and system for closed-loop control of an artificial pancreas |
US9474475B1 (en) | 2013-03-15 | 2016-10-25 | Abbott Diabetes Care Inc. | Multi-rate analyte sensor data collection with sample rate configurable signal processing |
US9492608B2 (en) | 2013-03-15 | 2016-11-15 | Tandem Diabetes Care, Inc. | Method and device utilizing insulin delivery protocols |
US9795737B2 (en) | 2013-03-15 | 2017-10-24 | Animas Corporation | Method and system for closed-loop control of an artificial pancreas |
US10016561B2 (en) | 2013-03-15 | 2018-07-10 | Tandem Diabetes Care, Inc. | Clinical variable determination |
US10433773B1 (en) | 2013-03-15 | 2019-10-08 | Abbott Diabetes Care Inc. | Noise rejection methods and apparatus for sparsely sampled analyte sensor data |
WO2014152034A1 (en) | 2013-03-15 | 2014-09-25 | Abbott Diabetes Care Inc. | Sensor fault detection using analyte sensor data pattern comparison |
US9561324B2 (en) | 2013-07-19 | 2017-02-07 | Bigfoot Biomedical, Inc. | Infusion pump system and method |
CN103520797B (en) * | 2013-11-04 | 2015-07-01 | 理康互联科技(北京)有限公司 | Closed-loop drug releasing system |
US10569015B2 (en) | 2013-12-02 | 2020-02-25 | Bigfoot Biomedical, Inc. | Infusion pump system and method |
EP3087548A4 (en) | 2013-12-26 | 2017-09-13 | Tandem Diabetes Care, Inc. | Safety processor for wireless control of a drug delivery device |
WO2015102745A1 (en) | 2013-12-31 | 2015-07-09 | Abbott Diabetes Care Inc. | Self-powered analyte sensor and devices using the same |
EP3125761B1 (en) | 2014-03-30 | 2020-09-30 | Abbott Diabetes Care Inc. | Method and apparatus for determining meal start and peak events in analyte monitoring systems |
EP3174577A4 (en) | 2014-07-30 | 2018-04-18 | Tandem Diabetes Care, Inc. | Temporary suspension for closed-loop medicament therapy |
US10971260B2 (en) | 2014-09-14 | 2021-04-06 | Becton, Dickinson And Company | System and method for capturing dose information |
US10704944B2 (en) | 2014-09-14 | 2020-07-07 | Becton, Dickinson And Company | System and method for capturing dose information |
WO2016061308A1 (en) | 2014-10-17 | 2016-04-21 | Kahlbaugh Bradley E | Human metabolic condition management |
US9636453B2 (en) | 2014-12-04 | 2017-05-02 | Medtronic Minimed, Inc. | Advance diagnosis of infusion device operating mode viability |
US9943645B2 (en) | 2014-12-04 | 2018-04-17 | Medtronic Minimed, Inc. | Methods for operating mode transitions and related infusion devices and systems |
US11183301B2 (en) * | 2015-05-18 | 2021-11-23 | Dexcom, Inc. | Individualized multiple-day simulation model of type 1 diabetic patient decision-making for developing, testing and optimizing insulin therapies driven by glucose sensors |
US10569016B2 (en) | 2015-12-29 | 2020-02-25 | Tandem Diabetes Care, Inc. | System and method for switching between closed loop and open loop control of an ambulatory infusion pump |
US10449294B1 (en) | 2016-01-05 | 2019-10-22 | Bigfoot Biomedical, Inc. | Operating an infusion pump system |
CN114053517A (en) | 2016-01-05 | 2022-02-18 | 比格福特生物医药公司 | Operating a multi-mode drug delivery system |
US10878964B2 (en) | 2016-01-12 | 2020-12-29 | President And Fellows Of Harvard College | Predictive control model for the artificial pancreas using past predictions |
AU2017207484B2 (en) | 2016-01-14 | 2021-05-13 | Bigfoot Biomedical, Inc. | Adjusting insulin delivery rates |
AU2017216336B2 (en) * | 2016-02-05 | 2020-12-10 | Animas Corporation | Visualization and analysis tool for a drug delivery system |
US11883630B2 (en) | 2016-07-06 | 2024-01-30 | President And Fellows Of Harvard College | Event-triggered model predictive control for embedded artificial pancreas systems |
GB201614676D0 (en) | 2016-08-30 | 2016-10-12 | Imp Innovations | Automatic closed-loop glucose control with an adaptive meal bolus calculator |
US10583250B2 (en) | 2017-01-13 | 2020-03-10 | Bigfoot Biomedical, Inc. | System and method for adjusting insulin delivery |
WO2018132754A1 (en) | 2017-01-13 | 2018-07-19 | Mazlish Bryan | System and method for adjusting insulin delivery |
US10758675B2 (en) | 2017-01-13 | 2020-09-01 | Bigfoot Biomedical, Inc. | System and method for adjusting insulin delivery |
US10500334B2 (en) | 2017-01-13 | 2019-12-10 | Bigfoot Biomedical, Inc. | System and method for adjusting insulin delivery |
US11033682B2 (en) | 2017-01-13 | 2021-06-15 | Bigfoot Biomedical, Inc. | Insulin delivery methods, systems and devices |
EP3568860A1 (en) | 2017-01-13 | 2019-11-20 | Bigfoot Biomedical, Inc. | Insulin delivery methods, systems and devices |
US11147920B2 (en) | 2017-04-18 | 2021-10-19 | Lifescan Ip Holdings, Llc | Diabetes management system with automatic basal and manual bolus insulin control |
ES2903174T3 (en) | 2017-05-05 | 2022-03-31 | Lilly Co Eli | Physiological glucose closed loop monitoring |
CN107277443B (en) * | 2017-06-23 | 2019-12-10 | 深圳市盛路物联通讯技术有限公司 | Large-range peripheral safety monitoring method and system |
EP3438858A1 (en) * | 2017-08-02 | 2019-02-06 | Diabeloop | Closed-loop blood glucose control systems and methods |
CN212438615U (en) | 2017-10-24 | 2021-02-02 | 德克斯康公司 | Wearable device |
US11331022B2 (en) | 2017-10-24 | 2022-05-17 | Dexcom, Inc. | Pre-connected analyte sensors |
US10803983B2 (en) | 2017-10-27 | 2020-10-13 | Miraclebots, LLC | System and method for auto-regulating drug administration for achieving artificial homeostasis |
US11901060B2 (en) | 2017-12-21 | 2024-02-13 | Ypsomed Ag | Closed loop control of physiological glucose |
CN112236826A (en) * | 2018-05-04 | 2021-01-15 | 英赛罗公司 | Safety constraints for drug delivery systems based on control algorithms |
US11224693B2 (en) | 2018-10-10 | 2022-01-18 | Tandem Diabetes Care, Inc. | System and method for switching between medicament delivery control algorithms |
US11464908B2 (en) | 2019-02-18 | 2022-10-11 | Tandem Diabetes Care, Inc. | Methods and apparatus for monitoring infusion sites for ambulatory infusion pumps |
US11911595B2 (en) | 2020-05-18 | 2024-02-27 | Tandem Diabetes Care, Inc. | Systems and methods for automated insulin delivery response to meal announcements |
CN112402732B (en) * | 2020-10-10 | 2023-05-05 | 广东食品药品职业学院 | Insulin infusion quantity control method based on self-adaptive control weighting factor strategy |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2007116226A2 (en) * | 2006-04-07 | 2007-10-18 | Cambridge Enterprise Limited | Blood glucose monitoring systems |
US20080161664A1 (en) * | 2006-12-29 | 2008-07-03 | Medtronic Minimed, Inc. | Method and System for Providing Sensor Redundancy |
Family Cites Families (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FI118509B (en) | 1996-02-12 | 2007-12-14 | Nokia Oyj | A method and apparatus for predicting blood glucose levels in a patient |
US7806886B2 (en) * | 1999-06-03 | 2010-10-05 | Medtronic Minimed, Inc. | Apparatus and method for controlling insulin infusion with state variable feedback |
US6423035B1 (en) * | 1999-06-18 | 2002-07-23 | Animas Corporation | Infusion pump with a sealed drive mechanism and improved method of occlusion detection |
US7460130B2 (en) * | 2000-09-26 | 2008-12-02 | Advantage 3D Llc | Method and system for generation, storage and distribution of omni-directional object views |
US7920906B2 (en) * | 2005-03-10 | 2011-04-05 | Dexcom, Inc. | System and methods for processing analyte sensor data for sensor calibration |
WO2005041103A2 (en) | 2003-10-29 | 2005-05-06 | Novo Nordisk A/S | Medical advisory system |
CA2612714C (en) * | 2005-05-13 | 2013-09-24 | Trustees Of Boston University | Fully automated control system for type 1 diabetes |
US7920907B2 (en) * | 2006-06-07 | 2011-04-05 | Abbott Diabetes Care Inc. | Analyte monitoring system and method |
US9056165B2 (en) * | 2006-09-06 | 2015-06-16 | Medtronic Minimed, Inc. | Intelligent therapy recommendation algorithm and method of using the same |
US20080172031A1 (en) * | 2006-10-17 | 2008-07-17 | Blomquist Michael L | Insulin pump having correction factors |
US10154804B2 (en) * | 2007-01-31 | 2018-12-18 | Medtronic Minimed, Inc. | Model predictive method and system for controlling and supervising insulin infusion |
EP4159114B1 (en) * | 2007-10-09 | 2024-04-10 | DexCom, Inc. | Integrated insulin delivery system with continuous glucose sensor |
US8527208B2 (en) * | 2008-11-17 | 2013-09-03 | Roche Diagnostics International Ag | Prandial blood glucose excursion optimization method via computation of time-varying optimal insulin profiles and system thereof |
US8062249B2 (en) * | 2009-03-31 | 2011-11-22 | Abbott Diabetes Care Inc. | Overnight closed-loop insulin delivery with model predictive control and glucose measurement error model |
-
2010
- 2010-03-31 US US12/751,668 patent/US8062249B2/en active Active
- 2010-03-31 EP EP10711525.5A patent/EP2413781B1/en active Active
- 2010-03-31 WO PCT/US2010/029492 patent/WO2010114929A1/en active Application Filing
-
2011
- 2011-09-22 US US13/240,855 patent/US8585637B2/en active Active
-
2013
- 2013-11-18 US US14/083,336 patent/US9402953B2/en active Active
-
2016
- 2016-06-27 US US15/193,804 patent/US20170080152A1/en not_active Abandoned
-
2019
- 2019-01-18 US US16/251,572 patent/US11246986B2/en active Active
-
2021
- 2021-08-10 US US17/398,221 patent/US20210361867A1/en active Pending
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2007116226A2 (en) * | 2006-04-07 | 2007-10-18 | Cambridge Enterprise Limited | Blood glucose monitoring systems |
US20080161664A1 (en) * | 2006-12-29 | 2008-07-03 | Medtronic Minimed, Inc. | Method and System for Providing Sensor Redundancy |
Non-Patent Citations (2)
Title |
---|
ANDREASSEN S ET AL: "A probabilistic approach to glucose prediction and insulin dose adjustment: description of metabolic model and pilot evaluation study", COMPUTER METHODS AND PROGRAMS IN BIOMEDICINE, ELSEVIER, AMSTERDAM, NL LNKD- DOI:10.1016/0169-2607(94)90052-3, vol. 41, no. 3-4, 1 January 1994 (1994-01-01), pages 153 - 165, XP024237284, ISSN: 0169-2607, [retrieved on 19940101] * |
ROMAN HOVORKA ET AL: "Nonlinear model predictive control of glucose concentration in subjects with type 1 diabetes; Controlling glucose", PHYSIOLOGICAL MEASUREMENT, INSTITUTE OF PHYSICS PUBLISHING, BRISTOL, GB LNKD- DOI:10.1088/0967-3334/25/4/010, vol. 25, no. 4, 1 August 2004 (2004-08-01), pages 905 - 920, XP020074167, ISSN: 0967-3334 * |
Cited By (96)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US10434246B2 (en) | 2003-10-07 | 2019-10-08 | Icu Medical, Inc. | Medication management system |
US11235100B2 (en) | 2003-11-13 | 2022-02-01 | Icu Medical, Inc. | System for maintaining drug information and communicating with medication delivery devices |
US11194810B2 (en) | 2006-10-16 | 2021-12-07 | Icu Medical, Inc. | System and method for comparing and utilizing activity information and configuration information from multiple device management systems |
US10242060B2 (en) | 2006-10-16 | 2019-03-26 | Icu Medical, Inc. | System and method for comparing and utilizing activity information and configuration information from multiple medical device management systems |
US10635784B2 (en) | 2007-12-18 | 2020-04-28 | Icu Medical, Inc. | User interface improvements for medical devices |
US10238801B2 (en) | 2009-04-17 | 2019-03-26 | Icu Medical, Inc. | System and method for configuring a rule set for medical event management and responses |
US11013861B2 (en) | 2009-04-17 | 2021-05-25 | Icu Medical, Inc. | System and method for configuring a rule set for medical event management and responses |
US11654237B2 (en) | 2009-04-17 | 2023-05-23 | Icu Medical, Inc. | System and method for configuring a rule set for medical event management and responses |
US10431342B2 (en) | 2009-09-02 | 2019-10-01 | University Of Virginia Patent Foundation | Tracking the probability for imminent hypoglycemia in diabetes from self-monitoring blood glucose (SMBG) data |
EP2473845A1 (en) * | 2009-09-02 | 2012-07-11 | University Of Virginia Patent Foundation | Tracking the probability for imminent hypoglycemia in diabetes from self-monitoring blood glucose (smbg) data |
EP2473845A4 (en) * | 2009-09-02 | 2014-04-30 | Univ Virginia Patent Found | Tracking the probability for imminent hypoglycemia in diabetes from self-monitoring blood glucose (smbg) data |
US11599854B2 (en) | 2011-08-19 | 2023-03-07 | Icu Medical, Inc. | Systems and methods for a graphical interface including a graphical representation of medical data |
US11004035B2 (en) | 2011-08-19 | 2021-05-11 | Icu Medical, Inc. | Systems and methods for a graphical interface including a graphical representation of medical data |
US10430761B2 (en) | 2011-08-19 | 2019-10-01 | Icu Medical, Inc. | Systems and methods for a graphical interface including a graphical representation of medical data |
US11626205B2 (en) | 2011-10-21 | 2023-04-11 | Icu Medical, Inc. | Medical device update system |
US9971871B2 (en) | 2011-10-21 | 2018-05-15 | Icu Medical, Inc. | Medical device update system |
US10022498B2 (en) | 2011-12-16 | 2018-07-17 | Icu Medical, Inc. | System for monitoring and delivering medication to a patient and method of using the same to minimize the risks associated with automated therapy |
US11376361B2 (en) | 2011-12-16 | 2022-07-05 | Icu Medical, Inc. | System for monitoring and delivering medication to a patient and method of using the same to minimize the risks associated with automated therapy |
US9995611B2 (en) | 2012-03-30 | 2018-06-12 | Icu Medical, Inc. | Air detection system and method for detecting air in a pump of an infusion system |
US11933650B2 (en) | 2012-03-30 | 2024-03-19 | Icu Medical, Inc. | Air detection system and method for detecting air in a pump of an infusion system |
US10578474B2 (en) | 2012-03-30 | 2020-03-03 | Icu Medical, Inc. | Air detection system and method for detecting air in a pump of an infusion system |
US10463788B2 (en) | 2012-07-31 | 2019-11-05 | Icu Medical, Inc. | Patient care system for critical medications |
US11623042B2 (en) | 2012-07-31 | 2023-04-11 | Icu Medical, Inc. | Patient care system for critical medications |
EP2943150A4 (en) * | 2013-01-14 | 2016-10-26 | Univ California | Daily periodic target-zone modulation in the model predictive control problem for artificial pancreas for type i diabetes applications |
US11470000B2 (en) | 2013-03-06 | 2022-10-11 | Icu Medical, Inc. | Medical device communication method |
US10333843B2 (en) | 2013-03-06 | 2019-06-25 | Icu Medical, Inc. | Medical device communication method |
US10335075B2 (en) | 2013-03-14 | 2019-07-02 | Dexcom, Inc. | Advanced calibration for analyte sensors |
US10046112B2 (en) | 2013-05-24 | 2018-08-14 | Icu Medical, Inc. | Multi-sensor infusion system for detecting air or an occlusion in the infusion system |
US10874793B2 (en) | 2013-05-24 | 2020-12-29 | Icu Medical, Inc. | Multi-sensor infusion system for detecting air or an occlusion in the infusion system |
US10166328B2 (en) | 2013-05-29 | 2019-01-01 | Icu Medical, Inc. | Infusion system which utilizes one or more sensors and additional information to make an air determination regarding the infusion system |
US10596316B2 (en) | 2013-05-29 | 2020-03-24 | Icu Medical, Inc. | Infusion system and method of use which prevents over-saturation of an analog-to-digital converter |
US11596737B2 (en) | 2013-05-29 | 2023-03-07 | Icu Medical, Inc. | Infusion system and method of use which prevents over-saturation of an analog-to-digital converter |
US11433177B2 (en) | 2013-05-29 | 2022-09-06 | Icu Medical, Inc. | Infusion system which utilizes one or more sensors and additional information to make an air determination regarding the infusion system |
US11571508B2 (en) | 2013-08-30 | 2023-02-07 | Icu Medical, Inc. | System and method of monitoring and managing a remote infusion regimen |
US10765799B2 (en) | 2013-09-20 | 2020-09-08 | Icu Medical, Inc. | Fail-safe drug infusion therapy system |
US10311972B2 (en) | 2013-11-11 | 2019-06-04 | Icu Medical, Inc. | Medical device system performance index |
US11501877B2 (en) | 2013-11-11 | 2022-11-15 | Icu Medical, Inc. | Medical device system performance index |
US11763927B2 (en) | 2013-11-19 | 2023-09-19 | Icu Medical, Inc. | Infusion pump automation system and method |
US10042986B2 (en) | 2013-11-19 | 2018-08-07 | Icu Medical, Inc. | Infusion pump automation system and method |
US11037668B2 (en) | 2013-11-19 | 2021-06-15 | Icu Medical, Inc. | Infusion pump automation system and method |
US10342917B2 (en) | 2014-02-28 | 2019-07-09 | Icu Medical, Inc. | Infusion system and method which utilizes dual wavelength optical air-in-line detection |
US11628246B2 (en) | 2014-04-30 | 2023-04-18 | Icu Medical, Inc. | Patient care system with conditional alarm forwarding |
US10898641B2 (en) | 2014-04-30 | 2021-01-26 | Icu Medical, Inc. | Patient care system with conditional alarm forwarding |
CN105079909A (en) * | 2014-05-06 | 2015-11-25 | 成都成电医星数字健康软件有限公司 | Infusion parameter calculating device and system |
US11344673B2 (en) | 2014-05-29 | 2022-05-31 | Icu Medical, Inc. | Infusion system and pump with configurable closed loop delivery rate catch-up |
US10314974B2 (en) | 2014-06-16 | 2019-06-11 | Icu Medical, Inc. | System for monitoring and delivering medication to a patient and method of using the same to minimize the risks associated with automated therapy |
US10646651B2 (en) | 2014-06-16 | 2020-05-12 | Icu Medical, Inc. | System for monitoring and delivering medication to a patient and method of using the same to minimize the risks associated with automated therapy |
US11628254B2 (en) | 2014-06-16 | 2023-04-18 | Icu Medical, Inc. | System for monitoring and delivering medication to a patient and method of using the same to minimize the risks associated with automated therapy |
US9724470B2 (en) | 2014-06-16 | 2017-08-08 | Icu Medical, Inc. | System for monitoring and delivering medication to a patient and method of using the same to minimize the risks associated with automated therapy |
CN106714874A (en) * | 2014-08-06 | 2017-05-24 | 加利福尼亚大学董事会 | Moving-horizon state-initializer for control applications |
CN106714874B (en) * | 2014-08-06 | 2019-10-08 | 加利福尼亚大学董事会 | Rolling time horizon state initialization device for control applications |
US11289183B2 (en) | 2014-09-15 | 2022-03-29 | Icu Medical, Inc. | Matching delayed infusion auto-programs with manually entered infusion programs |
US10238799B2 (en) | 2014-09-15 | 2019-03-26 | Icu Medical, Inc. | Matching delayed infusion auto-programs with manually entered infusion programs |
US10799632B2 (en) | 2014-09-15 | 2020-10-13 | Icu Medical, Inc. | Matching delayed infusion auto-programs with manually entered infusion programs |
US11574721B2 (en) | 2014-09-15 | 2023-02-07 | Icu Medical, Inc. | Matching delayed infusion auto-programs with manually entered infusion programs |
US11344668B2 (en) | 2014-12-19 | 2022-05-31 | Icu Medical, Inc. | Infusion system with concurrent TPN/insulin infusion |
US10850024B2 (en) | 2015-03-02 | 2020-12-01 | Icu Medical, Inc. | Infusion system, device, and method having advanced infusion features |
CN107530032A (en) * | 2015-04-29 | 2018-01-02 | 比格福特生物医学有限公司 | Operate infusion pump systems |
US11605468B2 (en) | 2015-05-26 | 2023-03-14 | Icu Medical, Inc. | Infusion pump system and method with multiple drug library editor source capability |
US11246985B2 (en) | 2016-05-13 | 2022-02-15 | Icu Medical, Inc. | Infusion pump system and method with common line auto flush |
US11324888B2 (en) | 2016-06-10 | 2022-05-10 | Icu Medical, Inc. | Acoustic flow sensor for continuous medication flow measurements and feedback control of infusion |
US11574737B2 (en) | 2016-07-14 | 2023-02-07 | Icu Medical, Inc. | Multi-communication path selection and security system for a medical device |
US11029911B2 (en) | 2017-12-27 | 2021-06-08 | Icu Medical, Inc. | Synchronized display of screen content on networked devices |
US10656894B2 (en) | 2017-12-27 | 2020-05-19 | Icu Medical, Inc. | Synchronized display of screen content on networked devices |
US11868161B2 (en) | 2017-12-27 | 2024-01-09 | Icu Medical, Inc. | Synchronized display of screen content on networked devices |
US20210059602A1 (en) * | 2018-01-16 | 2021-03-04 | The Regents Of The University Of California | Systems, devices and methods for estimating blood glucose concentrations from signals of sensors deployed in tissue |
WO2019143741A1 (en) * | 2018-01-16 | 2019-07-25 | The Regents Of The University Of California | Systems, devices and methods for estimating blood glucose concentrations from signals of sensors deployed in tissue |
US11139058B2 (en) | 2018-07-17 | 2021-10-05 | Icu Medical, Inc. | Reducing file transfer between cloud environment and infusion pumps |
US11152109B2 (en) | 2018-07-17 | 2021-10-19 | Icu Medical, Inc. | Detecting missing messages from clinical environment |
US11483402B2 (en) | 2018-07-17 | 2022-10-25 | Icu Medical, Inc. | Maintaining clinical messaging during an internet outage |
US11483403B2 (en) | 2018-07-17 | 2022-10-25 | Icu Medical, Inc. | Maintaining clinical messaging during network instability |
US11373753B2 (en) | 2018-07-17 | 2022-06-28 | Icu Medical, Inc. | Converting pump messages in new pump protocol to standardized dataset messages |
US11923076B2 (en) | 2018-07-17 | 2024-03-05 | Icu Medical, Inc. | Converting pump messages in new pump protocol to standardized dataset messages |
US11881297B2 (en) | 2018-07-17 | 2024-01-23 | Icu Medical, Inc. | Reducing infusion pump network congestion by staggering updates |
US11328805B2 (en) | 2018-07-17 | 2022-05-10 | Icu Medical, Inc. | Reducing infusion pump network congestion by staggering updates |
US11328804B2 (en) | 2018-07-17 | 2022-05-10 | Icu Medical, Inc. | Health checks for infusion pump communications systems |
US10741280B2 (en) | 2018-07-17 | 2020-08-11 | Icu Medical, Inc. | Tagging pump messages with identifiers that facilitate restructuring |
US11587669B2 (en) | 2018-07-17 | 2023-02-21 | Icu Medical, Inc. | Passing authentication token to authorize access to rest calls via web sockets |
US11594326B2 (en) | 2018-07-17 | 2023-02-28 | Icu Medical, Inc. | Detecting missing messages from clinical environment |
US11783935B2 (en) | 2018-07-17 | 2023-10-10 | Icu Medical, Inc. | Health checks for infusion pump communications systems |
US11152110B2 (en) | 2018-07-17 | 2021-10-19 | Icu Medical, Inc. | Tagging pump messages with identifiers that facilitate restructuring |
US11152108B2 (en) | 2018-07-17 | 2021-10-19 | Icu Medical, Inc. | Passing authentication token to authorize access to rest calls via web sockets |
US10861592B2 (en) | 2018-07-17 | 2020-12-08 | Icu Medical, Inc. | Reducing infusion pump network congestion by staggering updates |
US11670416B2 (en) | 2018-07-17 | 2023-06-06 | Icu Medical, Inc. | Tagging pump messages with identifiers that facilitate restructuring |
US10950339B2 (en) | 2018-07-17 | 2021-03-16 | Icu Medical, Inc. | Converting pump messages in new pump protocol to standardized dataset messages |
US10964428B2 (en) | 2018-07-17 | 2021-03-30 | Icu Medical, Inc. | Merging messages into cache and generating user interface using the cache |
US11437132B2 (en) | 2018-07-26 | 2022-09-06 | Icu Medical, Inc. | Drug library dynamic version management |
US11309070B2 (en) | 2018-07-26 | 2022-04-19 | Icu Medical, Inc. | Drug library manager with customized worksheets |
US10692595B2 (en) | 2018-07-26 | 2020-06-23 | Icu Medical, Inc. | Drug library dynamic version management |
WO2021108431A1 (en) * | 2019-11-25 | 2021-06-03 | Abbott Diabetes Care Inc. | Methods, devices, and systems for physiological parameter analysis |
US11278671B2 (en) | 2019-12-04 | 2022-03-22 | Icu Medical, Inc. | Infusion pump with safety sequence keypad |
US11883361B2 (en) | 2020-07-21 | 2024-01-30 | Icu Medical, Inc. | Fluid transfer devices and methods of use |
US11135360B1 (en) | 2020-12-07 | 2021-10-05 | Icu Medical, Inc. | Concurrent infusion with common line auto flush |
WO2023280915A1 (en) * | 2021-07-07 | 2023-01-12 | Fresenius Medical Care Deutschland Gmbh | Systems and methods for optimization of disease therapy |
EP4116986A1 (en) * | 2021-07-07 | 2023-01-11 | Fresenius Medical Care Deutschland GmbH | Systems and methods for optimization of disease therapy |
US11972395B2 (en) | 2023-02-01 | 2024-04-30 | Icu Medical, Inc. | Systems and methods for a graphical interface including a graphical representation of medical data |
Also Published As
Publication number | Publication date |
---|---|
US8585637B2 (en) | 2013-11-19 |
US20210361867A1 (en) | 2021-11-25 |
US20190151540A1 (en) | 2019-05-23 |
US9402953B2 (en) | 2016-08-02 |
EP2413781A1 (en) | 2012-02-08 |
US8062249B2 (en) | 2011-11-22 |
US11246986B2 (en) | 2022-02-15 |
EP2413781B1 (en) | 2019-07-24 |
US20120010600A1 (en) | 2012-01-12 |
US20140081236A1 (en) | 2014-03-20 |
US20170080152A1 (en) | 2017-03-23 |
US20100280441A1 (en) | 2010-11-04 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20210361867A1 (en) | Integrated closed-loop medication delivery with error model and safety check | |
JP6066499B2 (en) | Insulin pump | |
US20190019571A1 (en) | Method, System and Computer Program Product for Evaluation of Insulin Sensitivity, Insulin/Carbohydrate Ratio, and Insulin Correction Factors in Diabetes from Self-Monitoring Data | |
US8454510B2 (en) | Method and device for assessing carbohydrate-to-insulin ratio | |
JP5661651B2 (en) | Prevention of hypoglycemia based on CGM by assessing risk of hypoglycemia and reducing gentle insulin release | |
Jacobs et al. | Automated control of an adaptive bihormonal, dual-sensor artificial pancreas and evaluation during inpatient studies | |
Hovorka | The future of continuous glucose monitoring: closed loop | |
EP2174248B1 (en) | A method system and device for assessing insulin sensitivity | |
US8439897B2 (en) | Assessing residual insulin time | |
WO2011028731A1 (en) | System, method and computer program product for adjustment of insulin delivery (aid) in diabetes using nominal open-loop profiles | |
Jacobs et al. | Development of a fully automated closed loop artificial pancreas control system with dual pump delivery of insulin and glucagon | |
van Dijk et al. | Continuous intraperitoneal insulin infusion versus subcutaneous insulin therapy in the treatment of type 1 diabetes: effects on glycemic variability | |
Steil et al. | Closed-loop insulin delivery–what lies between where we are and where we are going? | |
Winkler et al. | Patient-specific performance evaluation for insulin control systems | |
Chassin et al. | Grading system to assess clinical performance of closed-loop glucose control | |
Deichmann et al. | Model predictive control to account for prolonged changes in insulin requirements following exercise in type 1 diabetes | |
Thabit et al. | Artificial pancreas: the bridge to a cure for type 1 diabetes | |
Wilinska et al. | Artificial Pancreas Systems: Overnight Closed-Loop Insulin Delivery with Model Predictive Control: Assessment of Hypoglycemia and Hyperglycemia Risk Using Simulation Studies | |
Wilinska et al. | Overnight closed-loop insulin delivery in patients with type 1 diabetes | |
Pejtersen et al. | Detection of events using continuous glucose monitors | |
Clarke et al. | Artificial Pancreas Systems: Closed-Loop Artificial Pancreas Using Subcutaneous Glucose Sensing and Insulin Delivery and a Model Predictive Control Algorithm: The Virginia Experience | |
Buckingham et al. | Creating an Artificial Pancreas—The Marriage of Insulin Pumps and Glucose Sensors |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 10711525 Country of ref document: EP Kind code of ref document: A1 |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2010711525 Country of ref document: EP |